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The concern about weight gain that usually accompanies smoking cessation is a substantial 
impediment to quitting for many women. Given that sustained-released (SR) bupropion is 
associated with decreased post-cessation weight gain (Jorenby et al., 1999), this pharmacological 
agent may be particularly effective in improving quit rates among weight-concerned women. 
Despite the increasing utilization of smoking cessation medications, such as bupropion, 
relatively little is known about adherence to these regimens. This study examined the rates, 
predictors, and sequalae of medication adherence among weight-concerned women participating 
in a 90-day smoking cessation program. In addition to receiving group behavior therapy, 
participants were randomized to receive either SR bupropion or placebo. Medication adherence 
was measured over time with electronic pill cap monitors, smoking cessation was measured by 
self-report and verified with carbon monoxide readings, and several psychosocial variables were 
assessed with self-report questionnaires. With 112 participants (91% Caucasian; mean age = 43, 
SD = 10 years), descriptive statistics were computed to summarize medication adherence, and 
linear and logistic regression analyses were used to predict medication adherence and prolonged 
smoking abstinence through the end of treatment, respectively. Overall medication adherence 
was less than optimal throughout the 90-day study period and adherence rates decreased during 
each successive 30-day period. Depending on the type of summary index, results indicated that 
medication adherence ranged from 26% to 73% over the 90-day period. Conscientiousness, 
 iv
openness to experience, social support and medication outcome expectancies measured at Week 
6 were positively associated with 90-day medication adherence. Independent of medication 
status, medication adherence predicted increased likelihood of maintaining prolonged smoking 
abstinence. Follow-up cross-lagged panel design analyses indicated that medication adherence 
significantly predicted subsequent point-prevalence abstinence. Moreover, openness to 
experience and Week 6 social support predicted increased likelihood of maintaining prolonged 
smoking abstinence, and post-hoc analyses indicated that medication adherence mediated the 
associations between openness to experience and prolonged abstinence, and between Week 6 
social support and prolonged abstinence. These results suggest that interventions designed either 
to modify psychosocial variables associated with medication adherence or to match treatments 
with individual differences may enhance adherence and possibly improve smoking cessation 
rates among weight-concerned women. 
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1 INTRODUCTION 
 
Adherence is the degree to which a person’s behavior (e.g., taking medications, following diets, 
or executing lifestyle changes) coincides with medical or health advice (Haynes, 1979).1 
Unfortunately, adherence is far less than optimal across a wide range of health behaviors and 
chronic illnesses (Kaplan & Simon, 1990; Dunbar-Jacob, Schlenk, Burke, & Matthews, 1998a). 
The importance of adherence to smoking cessation treatment is underscored by the fact that 
cigarette smoking is the single most preventable cause of premature morbidity and mortality in 
the United States (United States Department of Health and Human Services [USDHHS], 1994). 
After decades of disproportionately higher rates of male smokers, the prevalence of smoking is 
now nearly equal between men (25%) and women (21%; Centers for Disease Control, 1999). 
One reason for the equalization of smoking rates is the failure of women to quit smoking as 
readily as men (Ockene, 1993). The concern about weight gain that usually accompanies 
smoking cessation is a substantial impediment to quitting for many women. Given that sustained-
released (SR) bupropion is associated with decreased post-cessation weight gain (Jorenby et al., 
1999), this pharmacological agent may be particularly effective in improving quit rates among 
weight-concerned women. 
                                                 
1Other terms have been used to describe this process, including noncompliance, non-cooperation, or patient 
resistance. Since “adherence” suggests more voluntary action on the part of the patient, and for the sake of 
consistency, this term is used throughout this report. 
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Despite the increasing utilization of pharmacological agents, such as bupropion, 
relatively little is known about rates and predictors of smoking cessation pharmacotherapy 
adherence. A review of the literature on adherence to other health behaviors and chronic disease 
regimens suggested that six psychosocial characteristics, depressive symptoms, agreeableness, 
conscientiousness, social support, expectancies, and medication side effects, have conceptual and 
empirical promise. Thus, two primary aims of the present study were to characterize rates of 
medication adherence among a sample of female weight-concerned smokers participating in a 
smoking cessation clinical trial and to examine the extent to which these conceptually relevant 
psychosocial variables predict medication adherence. In addition, because adherence to the 
treatment regimen was expected to enhance smoking cessation outcome, the sequelae of 
treatment adherence were explored. It is important to note adherence to active and inactive 
medication was expected to improve smoking cessation rates. Therefore, another aim of this 
study was to examine the main effect of medication regimen adherence on smoking cessation. 
Two final goals were to determine whether any of the aforementioned psychosocial parameters 
influenced the hypothesized relationship between adherence and smoking cessation or whether 
medication adherence influenced any observed relationships among the psychosocial variables 
and smoking cessation. 
1.1 SMOKING AND WEIGHT CONCERNS AMONG WOMEN 
As noted, concerns about post-cessation weight gain deter many women from quitting smoking. 
A majority of female smokers state that they have weight concerns related to quitting smoking 
(Pirie, Murray, & Luepker, 1991). Among young female smokers, almost 40% state that they 
smoke to manage weight (Klesges & Klesges, 1988) and, in comparison to men, women are 
three to four times more likely to cite weight gain as a determinant of relapse (Swan, Ward, 
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Carmelli, & Jack, 1993). Meyers et al. (1997) observed that weight-concerned smokers (80% 
women) fared significantly worse in quitting at 12 months in comparison to non-weight 
concerned smokers. Perkins et al. (2001) randomly assigned weight-concerned women to three 
adjunct treatments accompanying group smoking cessation counseling: (1) behavioral weight 
control, (2) cognitive-behavior therapy (CBT) to reduce weight concerns, and (3) standard 
counseling. Although results showed that CBT to reduce weight concerns group improved 
smoking cessation relative to the other conditions, the overall cessation rates were somewhat 
disappointing at 12 months follow-up (continuous abstinence rates): behavioral weight control 
group = 18%, (2) CBT to reduce weight concerns group = 21%, and (3) standard group = 9%. 
For this reason, Perkins et al. (2001) suggested that conjoint CBT to reduce weight concerns and 
smoking cessation pharmacotherapy might enhance quit rates to an even greater degree among 
weight-concerned women.  
Bupropion is a pharmacological agent that may be beneficial in ameliorating weight gain 
and other factors particularly relevant to women’s cessation efforts (e.g, depressive symptoms). 
Originally classified as an antidepressant (Wellbutrin®, GlaxoSmithKline, plc.), bupropion has 
been shown to be an effective treatment for mild to severely depressed individuals (Feighner, 
Meredith, Stern, Hendrickson, & Miller, 1984; Pitts et al., 1983; Zung, 1983). Subsequent 
investigations established the clinical efficacy of bupropion for smoking cessation (Hurt et al., 
1997; Jorenby et al., 1999; Hays et al., 2001). The mechanisms by which bupropion facilitates 
smoking cessation are not known. However, two possible explanations include reductions in 
negative emotions and weight gain associated with quitting smoking. Shiffman and colleagues 
(2000) reported that bupropion attenuated negative affect and withdrawal among smokers who 
quit for a short time. Also, Hurt et al. (1997) observed that bupropion may influence weight gain 
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associated with smoking cessation. Independent of weight concerns, both men and women 
gained significantly less weight in a dose-response manner after seven weeks of treatment. That 
is, after seven weeks of treatment, the placebo group gained 2.9 kg, bupropion 100 mg group 
gained 2.3 kg, the 150 mg group gained 2.3 kg, and 300 mg group gained 1.5 kg (Hurt et al., 
1997). Jorenby et al. (1999) and Hays et al. (2001) also reported that bupropion attenuated post-
cessation weight gain, and in two other trials Anderson et al. (2002) and Jain et al. (2002) 
showed that bupropion facilitates weight loss in obese individuals. Finally, nicotine replacement 
treatments have not been as successful with women as with men (Perkins, 1996) and bupropion 
has been shown to be an effective treatment for preventing smoking relapse among women 
(Gonzales et al., 2002). In summary, bupropion was selected as the pharmacological agent in the 
larger clinical trial because of its potential utility for smoking cessation in weight-concerned 
women.2  
1.2 HEALTH-RELATED ADHERENCE 
Health-related adherence is critical for the prevention, treatment, and empirical examination of 
diseases for many reasons. From a clinical point of view, poor adherence to treatment can lead to 
incorrect diagnoses and patient and health-care provider frustration (Haynes, Taylor, & Sackett, 
1979). In certain circumstances, failure to adhere to medical regimens may result in serious 
consequences. For instance, low adherence rates among individuals with chronic medical 
                                                 
2 The overall clinical trial is also designed to examine the efficacy of group smoking cessation counseling: 
cognitive-behavioral therapy to ameliorate post-cessation weight concerns versus standard smoking cessation 
counseling. Since the effects of medication and counseling treatments were not the focus of the present study, these 
factors were assessed for the possibility of confounding medication adherence analyses, and if necessary, 
statistically adjusted for in such cases (see Data Analytic Plan section). 
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illnesses have been associated with increased hospital admissions and longer hospital stays 
(Dunbar-Jacob, Burke, & Puczynski, 1995). Nonadherence may play an important role in the 
reemergence of drug-resistant organisms, including tuberculosis (Gourevitch, Wasserman, 
Panero, & Selwyn, 1996) and human immunodeficiency virus (HIV; Mellors, 1997). 
Nonadherence to treatment requirements for chronic diseases, such end-stage renal disease, is 
associated with serious medical complications and earlier mortality (Plough, 1992). 
Unfortunately, satisfactory adherence across a range of chronic disease regimens is as low as 15-
20% (Myers & Midence, 1998), and consequently, the annual cost of nonadherence to medical 
treatment in the United States has been estimated to be $100 billion (Grahl, 1994). Treatment 
adherence is critical from a research perspective, as well. Poor adherence may complicate and 
even jeopardize interpretation of findings from clinical trials by reducing the overall group 
differences in response to treatment. In turn, additional costs may be incurred due to substantial 
increases in the number of participants required to preserve required statistical power (Dunbar-
Jacob, Sereika, Rohay, & Burke, 1998b). In sum, patient nonadherence may significantly 
contribute to treatment failures in medical and psychological interventions and, thus, poses a 
significant problem for health care delivery and research. 
In light of the potentially severe consequences of nonadherence to health regimens, the 
identification of factors that predict adherence has received considerable attention. When 
concomitants of nonadherence are identified, appropriate interventions may be developed to 
improve patient adherence and ultimately health outcomes (DiMatteo, Lepper, & Croghan, 
2000). Unfortunately, relatively little is known about the predictors of adherence to 
pharmacological smoking cessation treatments. 
 5
1.3 PREDICTORS OF ADHERENCE TO PHARMACOLOGICAL SMOKING 
CESSATION TREATMENT 
Recent clinical practice guidelines on treating tobacco dependence indicate that SR bupropion 
has the highest empirical record of efficacy among first-line cessation-related pharmacotherapies 
(Fiore et al., 2000). Despite this and other endorsements (e.g., Hughes, Stead, & Lancaster, 2002; 
Hughes, Goldstein, Hurt, & Shiffman, 1999) and bupropion’s increasing popularity3, published 
clinical trials examining the effects of bupropion on smoking cessation have not included 
information about regimen adherence (i.e., Hurt et al., 1997; Jorenby et al., 1999; Hays et al., 
2001) Although there are published data on predictors of adherence to antidepressants among 
depressed individuals (e.g., Demyttenaere, Van Ganse, Gregoire, Gaens, & Mesters, 1998), these 
findings are inconsistent and have minimal generalizability to the present study, as individuals 
with current mood disorders were excluded.  
Several nicotine replacement studies have included measures of adherence, but for the 
most part these studies inadequately define and measure adherence (Alterman, Gariti, Cook, & 
Cnaan, 1999; Fiore, Smith, Jorenby, & Baker, 1994). Two studies have reported on predictors of 
nicotine replacement adherence. Alterman et al. (1999) examined several potential predictors of 
nicotine patch adherence, including sociodemographics, nicotine dependence, withdrawal 
symptomatology, motivation to quit smoking, current and past psychopathology, and level of 
self-efficacy to quit smoking. Multiple regression analysis revealed three significant predictors of 
adherence—nicotine dependence, motivation to change, and psychosocial treatment condition—
that accounted for 18% of the variance of days of patch use. In a study of nicotine gum 
adherence, individuals who reported higher self-efficacy to refrain from smoking in tempting 
                                                 
3 Bupropion is licensed for the treatment of tobacco dependence in over 50 countries worldwide (Hays & Ebbert, 
2003); U.S. sales of bupropion (as a smoking cessation aid) exceeded $90 million in 2001 (GlaxoSmithKline, 2002). 
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situations were more likely to report higher adherence to gum use recommendations (Millard, 
Waranch, & McEntee, 1992). However, inferences from this study are suspect given the use of 
self-reported gum usage and the lack of a placebo group. Although the results from these two 
studies are interesting, it is clear that more research is needed to determine what other variables 
predict the majority of unaccounted variance in adherence to cessation-related pharmacological 
treatments, particularly bupropion. For this reason, the present study explored the role of several 
psychosocial variables that may facilitate the prediction of pharmacotherapy adherence. 
1.4 PSYCHOSOCIAL PREDICTORS OF ADHERENCE 
Because there are so few published findings on smoking cessation pharmacotherapy adherence, 
existing “theory” would consist of empirically unsubstantiated hunches about this behavior 
(Menard, 2002). Fortunately, the research on adherence to other health behavior change and 
disease treatment regimens has increased dramatically over the past quarter century, with 16,124 
articles on medication adherence published between 1976-1999 (Trostle, 2000), and has 
provided a wealth of information about plausible predictors of adherence to smoking cessation 
pharmacotherapy. Not surprisingly, there are a substantial number of variables that have been 
linked with adherence, but consistent findings across studies have been lacking (Dunbar-Jacob et 
al., 1998b). It has been difficult to interpret available evidence due to the heterogeneous nature of 
extant studies, including divergent disease characteristics, regimen behaviors, classifications of 
adherence, and approaches of assessing adherence (Dunbar-Jacob et al., 1998b). The use of 
several theoretical models, including the Health Belief Model, the Theory of Reasoned Action, 
the Theory of Planned Behavior, Attrition Theory, and the Self-Regulatory Model, have yielded 
inconsistent results, and have generally been unsupported in the prediction of adherence to 
several disease and health behavior change regimens (Clark & Becker, 1998; Horne & Weinman, 
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1998). Although research with the Stages of Change Model in the prediction of health behavior 
change has yielded some interesting findings in the area of smoking cessation (DiClemente & 
Prochaska, 1998), substantial criticism of the model on conceptual grounds has partly 
undermined the importance of this body of research (e.g., Weinstein, Rothman, & Sutton, 1998). 
For these reasons, a multivariate, exploratory approach was used in the process of selecting 
psychosocial predictors for inclusion in this study. 
When choosing variables for multivariate research, it is optimal to utilize a small number 
of valid variables that cover all of the theoretically important dimensions of a research area 
(Tabachnick & Fidell, 1996). An examination of three notable reviews of predictors of adherence 
(Haynes, 1979; Kaplan & Simon, 1990; Dunbar-Jacob et al., 1998a) offered several distinct, yet 
complementary areas of adherence predictors. Specifically, the dimensions of mood, personality, 
social support, social-cognition, and somatization appeared to be the most relevant and inclusive. 
Based on empirical and conceptual grounds, several psychosocial characteristics within these 
five dimensions—depression, conscientiousness, agreeableness, expectations, and side effects—
were thought to offer the most promise in explaining individual differences in smoking cessation 
pharmacotherapy adherence. In the following sections, findings on these putative predictors of 
adherence are reviewed, including results from a diverse range of health regimens and diseases, 
and from the smoking cessation literature when available. 
1.4.1 Depression  
Individuals with depressive symptomatology and a history of major depression disorder (MDD) 
have increased risk of poor health outcomes, including higher rates of cardiovascular morbidity 
and mortality (Musselman, Evans, & Nemeroff, 1998). Although depression may have direct 
physiological effects on disease pathogenesis, it is also likely that behavioral mediators are also 
at play (Musselman et al., 1998). Specifically, poor treatment adherence may be a primary 
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behavioral manifestation of depression. Depression tends to diminish concentration, energy, and 
motivation, which in turn may negatively influence an individual’s willingness and capacity to 
adhere to a treatment regimen (DiMatteo et al., 2000). Although the link between depression and 
nonadherence has not been demonstrated consistently (Dunbar-Jacob et al., 1998a), a recent 
meta-analysis of studies correlating medical patients’ treatment nonadherence with depression 
supports the relationship. DiMatteo et al. (2000) reviewed 12 published studies that examined 
recommendations given by physicians across several diseases, including end-stage renal disease 
and kidney transplantation, cancer, general medicine, angina, and rheumatoid arthritis. Eleven of 
the 12 studies showed a significant negative association between depression (primarily measured 
symptomatically, e.g., Beck Depression Inventory; Beck, Ward, Mendelson, Mock, & Erbaugh, 
1961) and adherence. Patients with higher levels of depression were three times as likely as 
patients with lower levels to be poor adherers (DiMatteo et al., 2000).  
Few studies have directly examined the association between depression and adherence to 
pharmacological smoking cessation treatment. Ginsberg et al. (1997), however, in a notable 
exception, examined whether a history of depression in female smokers (age 18-65) who did not 
self-report a current MDD episode was associated with adherence to multi-session, multi-
component smoking cessation treatment that included nicotine replacement. Results indicated 
that there was no effect of history of MDD on adherence to treatment, as measured by chewed 
nicotine gum returned to the clinic and counseling attendance. Unfortunately, depressed 
symptoms were not assessed, so it is unclear how sub-clinical mood symptoms influenced 
adherence.  
It is plausible that depressive symptomatology may predict treatment adherence among 
weight-concerned women. History of MDD and level of current depressive symptomatology has 
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been linked with increased rates of smoking (Acierno, Kilpatrick, Resnick, Saunders, & Best, 
1996; Lumley, Downey, Stetner, Wehmer, & Pomerleau, 1994). Individuals with a history of 
MDD have greater difficulty with quitting smoking (Breslau, Kilbey, & Andreski, 1992). In a 
previous study with weight-concerned women attempting to quit smoking, 52% had a history of 
mood disorder and some participants manifested significant current depressive symptomatology 
(Levine, Marcus, & Perkins, 2003). Although women with current MDD were excluded from the 
present study, it is likely that many participants had a history of mood disorder and current 
depressive symptoms. With the exception of the findings by Ginsberg et al. (1997), the weight of 
the evidence suggests that depression may be associated with poorer adherence to 
pharmacological smoking cessation treatment among weight-concerned women.  
Although depressive and anxiety symptoms often coexist, the meta-analysis by Dimatteo 
and colleagues (2000) found no consistent relationship between anxiety and treatment adherence. 
For this reason, anxiety was not examined in this study. 
1.4.2 Personality  
Several researchers have concluded that the empirical literature provides minimal support for 
associations between personality traits and treatment adherence (Haynes, Taylor, Snow, & 
Sackett, 1979, 1979; Kaplan & Simon, 1990; Horne, 1998; Dunbar-Jacob et al., 1998a). 
However, this conclusion may have been premature given that the personality and health 
literature has been severely hampered by the use of numerous measures indexing narrowly 
defined and likely overlapping constructs (Smith & Williams, 1992; Marshall, Wortman, 
Vickers, Kusulas, & Hervig, 1994). In their extensive review of 853 original articles, 
methodological articles, and reviews/commentaries, Haynes et al. (1979) found no associations 
between Minnesota Multiphasic Personality Inventory (MMPI) scales, the most commonly used 
measure, and patient adherence in the preponderance of studies. Given that the MMPI was 
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originally constructed to differentiate individuals with and without clinical psychopathology 
(Butcher, Graham, Dahlstrom, Tellegen, & Kaemmer, 1989), it is not surprising that studies 
reviewed by Haynes et al. (1979) did not report significant associations between MMPI profiles 
and adherence among a range of non-clinical populations (e.g., college students, medical 
populations). In addition, as will be discussed below, the implications of these null findings 
should not be over-generalized given that reliable and valid measures of adherence were not yet 
developed and utilized in a majority of the studies conducted in the 1960s and 1970s.  
On the other hand, in their extensive review Haynes and Sackett (1976) reported significant, 
albeit small, correlations between adherence and the wide range of “personality” characteristics, 
including active vs. passive orientation, futuristic orientation, work orientation, frustration 
tolerance, feelings of loneliness, motivation, unreliable personality type, immaturity, avoiding 
responsibility, impulsivity, responsiveness/cooperativeness, authoritariantism, and 
articulateness/intelligence. Many of these early findings were based on subjective ratings from 
clinical interviews, which are subject to interviewer biases and lack generalizability across 
studies (Wiebe & Christensen, 1996). Also, such a hodge-podge of individual difference 
measures are without a central theoretical schema, so it is difficult to reach firm conclusions 
about the implications of these findings. Other standardized personality measures have not 
received much attention in the adherence literature. Therefore, it is possible that applying a more 
systematic model of personality may be fruitful in the prediction of adherence to treatment 
regimens.  
During the past two decades, there has been a resurgence of interest in a five-factor 
taxonomy of personality dispositions (Smith & Williams, 1992). The NEO Personality 
Inventory-Revised (NEO-PI-R) and its short-form, the NEO Five Factor Inventory (NEO-FFI; 
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Costa & McCrae, 1992), incorporate one of the leading operationalizations of the five-factor 
model. There are now extensive data supporting the reliability and construct validity of the five 
NEO factors—conscientiousness, agreeableness, neuroticism, extraversion, and openness to 
experience (Costa & McCrae, 1992). Concurrently, there has been growing appreciation for the 
potential utility of a five-factor model in elucidating personality correlates of health-related 
outcomes (Smith & Williams, 1992). Wiebe and Christensen (1996) proposed that, if used 
consistently, the five-factor model of personality would bring a central theoretical organization 
to the personality and health literature. As such, this structure would minimize variability in the 
field, permit significant accumulation of empirical findings, and organize the direction of future 
research (Smith & Williams, 1992). Another benefit of using the NEO-FFI is that it does not 
include any health-related items and therefore obviates confounding with health outcomes 
(Booth-Kewley & Vickers, 1994). Although the utilization of the five-factor personality model in 
characterizing patient adherence to health or medical regimens has potential, applications have 
been relatively few to date. An inspection of the five-factor model reveals two dimensions—
conscientiousness and agreeableness—that may most accurately describe qualities important for 
regimen adherence. Although it is possible that the other three dimensions of the Five-Factor 
Model of Personality—neuroticism, openness to experience, and extraversion—are relevant to 
health-related behaviors, these factors seemed less conceptually and empirically relevant to 
medication adherence. For instance, previous research with the NEO-FFI reported non-
significant associations between composite indices of health behaviors and neuroticism, 
openness to experience, and extraversion (Booth-Kewley & Vickers, 1994; Lemos-Giraldez & 
Fidalgo-Aliste, 1997). For this reason and for the sake of parsimony, the effects of the latter three 
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personality dimensions on medication adherence and smoking cessation were assessed in 
secondary analyses. 
1.4.2.1 Conscientiousness   
Conscientious is a cluster of traits that include both self-restraint (order, dutifulness, and 
deliberation) and active striving to achieve goals. Individuals scoring high on this dimension are 
hardworking, persistent, and highly motivated; individuals scoring low are easygoing and 
moderately disorganized, and lack a clear direction in their lives (McCrae & Stone, 1997). 
Conscientious individuals are presumably also the most likely to adhere faithfully to prescribed 
medical regimens (Christensen & Smith, 1995). A recent seven-decade longitudinal study with 
1,178 males and females reported that conscientiousness in childhood was robustly related to 
survival in middle age and old age (Friedman et al., 1993), and it is possible that various health 
behaviors, including adherence to medical regimens, were responsible (Friedman et al., 1995). 
Booth-Kewley and Vickers (1994) found that high conscientiousness scores on the NEO-PI 
predicted of wellness behaviors (e.g., exercise, vitamin taking), accident control (e.g., learning 
first aid), and low traffic-related risk-taking. Lemos-Giraldez and Fidalgo-Aliste (1997) reported 
that conscientiousness scores from a Spanish-translated version of the NEO-FFI predicted a 
global measure of 15 health-related behaviors, including decreased smoking and alcohol 
consumption, increased exercise, and a balanced, moderate low-fat diet. Christenesen and Smith 
(1995) found that the NEO-FFI conscientiousness scale was significantly associated with 
medication adherence among end-stage renal disease patients, but failed to replicate this direct 
relationship in another study (Wiebe & Christensen, 1997). Christensen (2000) reported that a 
patient-by-treatment context interaction might explain their inconsistent findings. That is, among 
individuals given more responsibility for adhering to their hemodialysis treatment (i.e., 
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peritoneal dialysis at home), individuals with a more active coping style were more adherent 
(Christensen, 2000). Since patients in the present study had complete autonomy for adhering to 
their medication regimen, it was expected that highly conscientiousness individuals would 
manifest higher rates of adherence.  
1.4.2.2 Agreeableness 
Agreeableness is one of the more interpersonal dimensions of the five-factor model 
(Smith & Williams, 1992). Individuals scoring high on agreeableness are prosocial, compliant, 
accepting, honest, and straightforward. Individuals scoring low are hostile, suspicious, devious, 
demanding, and manipulative (McCrae & Stone, 1997). Booth-Kewley & Vickers (1994) found 
that individuals low in NEO-PI agreeableness engaged in significantly fewer wellness and 
accident control behaviors, and increased traffic-related risk-taking. Also, as agreeableness is 
inversely related to hostility (Smith & Williams, 1992), the findings of Booth-Kewley & Vickers 
(1994) are consistent with other research associating hostility with unhealthy behaviors (e.g., 
Leiker & Hailey, 1988; Smith, 1992). In the context of research showing that hostility leads to 
physical disease (Miller et al., 1996), it is possible that hostile individuals have increased health 
risks due to poor health habits, possibly including poor adherence to medical regimens. 
Given that adherence is thought to be partly due to the interaction between a patient and a 
health care provider (Griffith, 1990), it seems logical to assume that individuals low in 
agreeableness may not trust in the prescribed treatment regimen and thereby manifest poorer 
adherence. Few researchers have tested this hypothesis. A literature search revealed only two 
studies examining the effects of hostility on medication adherence. Lee and colleagues (1992) 
studied the impact of hostility on adherence to antihypertensive medication among 620 
hypertensive men. Individuals scoring high on the Hostility Scale of the Brief Symptom 
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Inventory (Derogatis & Melisaratos, 1982) reported missing more medication doses compared to 
those scoring low on the Hostility Scale. Christensen, Wiebe, and Lawton (1997) examined the 
effect of cynical hostility on regimen adherence among 48 hemodialysis patients. A hierarchical 
regression analysis revealed that Cook-Medley Hostility (Cook & Medley, 1954) scores 
significantly predicted poorer medication and dietary adherence. However, an interaction 
between hostility and Powerful Others Health Locus of Control (Wallston, Wallston, & DeVillis, 
1978) scale indicated that the effect of hostility was strongest among individuals believing that 
positive health outcomes are not a function of powerful others, such as health care providers. The 
results of these two studies suggest that low levels of agreeableness may lead to poorer 
medication adherence. 
1.4.3 Social Support 
Social support is a broad construct that is defined and measured in multiple ways. One popular 
approach is to operationalize social support as the extent to which an individual perceives 
various supportive functions to be available from his or her social relationships (Sarason & 
Sarason, 1994). The supportive functions include emotional (e.g., sharing feelings), 
informational (e.g., advice), instrumental (e.g., money), and tangible support (e.g., 
companionship; Sarason & Sarason, 1994). Thus, measures of perceived social support index the 
extent to which an individual knows other people who could provide these kinds of resources if a 
need existed. The notion that social support is a determinant of adherence has inherent appeal. 
That is, the greater the availability of useful help from close others, the more likely that an 
individual will be motivated and capable of adhering to treatment regimens. 
Social support has been associated with a variety of health outcomes, including mortality 
(House, Landis, & Umberson, 1988; Rosengren, Orth-Gomer, Wedel, & Wilhelmsen, 1993). 
Health behaviors, in part, may explain these associations. A wide range of studies suggests that 
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the perceived social support significantly predicts adherence across a variety of health domains 
(Haynes et al., 1979; Levy, 1983). Moreover, Morisky, DeMuth, Field-Fass, Green, and Levine 
(1985) randomly assigned hypertensive patients to a program designed to increase family social 
support for treatment adherence or to a control group. Patients in the support condition 
demonstrated significantly higher treatment adherence (i.e., with medication, appointment-
keeping, and weight control) and reduced blood pressure over a three-year period. More recently, 
social support has been associated with patient adherence to a variety of chronic disease 
regimens, including diabetes regimens (Sherbourne, Hays, Ordway, DiMatteo, & Kravitz, 1992), 
hemodialysis (Christensen et al., 1992), and HIV regimens (Catz, Kelly, Bogart, Benotsch, & 
McAuliffe, 2000). However, an association between perceived support and adherence has not 
been consistently found (Moran, Christensen, & Lawton, 1997). The equivocal results may be 
attributable, in part, to the psychometric inadequacy of several social support measures 
(Heitzmann & Kaplan, 1988). In the current study, the Interpersonal Support Evaluation List 
(ISEL; Cohen, Mermelstein, Kamarck, & Hoberman, 1985), an instrument with adequate 
psychometric properties, was used to examine whether perceived social support is predictive of 
medication adherence.  
1.4.4 Expectancies 
Bandura’s social learning theory (1977) has provided a useful framework for studying a variety 
of health-related behaviors, including treatment adherence. Two core constructs of social 
learning theory relevant to adherence are self-efficacy and outcome expectancies. Self-efficacy 
expectancies are beliefs that one can successfully perform the actions required to achieve valued 
outcomes. Relative to individuals with low self-efficacy expectations, those with high self-
efficacy expectations are thought to be more likely to initiate a behavior, expend more effort, and 
sustain a behavior while experiencing obstacles (Bandura, 1977). Accordingly, individuals 
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possessing greater adherence-related self-efficacy beliefs would be expected to exert more effort 
and persist more in the face of obstacles, resulting in higher adherence to the treatment regimen. 
In fact, lower self-efficacy expectations for treatment adherence have been related with 
subsequently poorer adherence to a variety of disease regimens, including fluid intake adherence 
among chronic hemodialysis patients (Brady, Tucker, Alfino, Tarrant, & Finlayson, 1997), 
adherence to a rheumatoid arthritis medication (Brus, van de Laar, Taal, Rasker, & Wiegman, 
1999), adherence to home glucose testing, diet, and exercise behaviors among individuals with 
type 2 diabetes (Skelly, Marshall, Haughey, Davis, & Dunford, 1995), and antiretroviral 
medications among HIV+ patients (Catz et al., 2000).  
Although there is a substantial literature on the relationship between self-efficacy 
expectancies and smoking cessation (often referred to as “abstinence self-efficacy;” Gwaltney, 
2000), these efficacy expectancies often pertain to perceived coping abilities across a range of 
conditions (e.g., feelings, arousal levels, environmental stressors) that may lead to smoking 
relapse (Gwaltney et al., 2001). However, there have been no apparent attempts to examine how 
self-efficacy expectancies affect adherence to smoking cessation treatments, including 
bupropion. Since self-efficacy expectancies are behavior specific and are not considered to 
comprise a trait (Maddux, 1999), a goal of the present study was to examine the extent to which 
adherence-related self-efficacy expectancies prospectively influence actual adherence to the 
medication regimen.  
Outcome expectancies are the beliefs that certain actions will led to specific outcomes in 
particular situations (Bandura, 1977). With respect to treatment adherence, individuals who 
believe that taking their medication will lead to better health outcomes may be more likely to 
adhere to their medication regimen than those who do not hold this belief. Outcome 
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expectancies, or perceived benefits, are a central component of the Health Belief Model (HBM), 
one of the most commonly applied models to adherence (Clark & Becker, 1998). Janz and 
Becker (1984) reviewed 46 studies of adherence to preventive health and disease regimens, and 
found that positive outcome expectancies or perceived benefits were significant in 78% of the 
studies. In a meta-analysis of the studies in Janz and Becker’s (1984) review, Booth-Kewley and 
Vickers (1994) reported a significant relationship (r = .33) between positive outcomes 
expectancies and health-promoting behaviors.  
In the nicotine literature, the focus of research has been on the expectancies of smoking 
itself (e.g., smoking as a stress reliever) and how these beliefs affect a range of smoking 
behaviors, including current nicotine use and dependence, the initiation of smoking, cessation 
attempts and outcomes, and nicotine withdrawal symptoms (Brandon, Juliano, & Copeland, 
1999). For instance, Gottlieb, Killen, Marlatt, and Taylor (1987) used a balanced placebo design 
to manipulate expectancies and pharmacological treatment for smoking cessation. In this study, 
109 smokers attempting to quit were randomly assigned to nicotine gum or placebo gum and 
were randomly told they were receiving nicotine gum or placebo. Participants who reported that 
they were receiving nicotine gum smoked fewer cigarettes during the first week of quitting in 
comparison to those who believed they were receiving placebo gum. Interestingly, the actual 
nicotine content of gum did not affect relapse. Despite the assessment of smoking expectancies 
in several other experimental and observational studies, outcome expectancies in reference to 
behaviors involved with quitting smoking, such as adherence to pharmacotherapy, apparently 
have not been examined. 
Bandura’s social learning model (1977) posits that self-efficacy and outcome 
expectancies are orthogonal and should be examined conjointly in the prediction of behavior 
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change. However, the two variables are often correlated and, as a result, it is common that only 
one predicts the health outcome. For instance, Skelly et al. (1995) examined the relationships 
between self-efficacy and outcome expectancies and adherence to a diabetes regimen consisting 
of home glucose testing, medication/insulin administration, diet, and exercise. The correlation 
between outcomes and efficacy expectancies was .75, and when both variables were entered into 
a multiple regression model, only efficacy expectations were a significant predictor of adherence. 
Similarly, in a study of fluid intake adherence among hemodialysis patients, adherence self-
efficacy and outcome expectancies were both entered into multiple regression model, but only 
self-efficacy expectancies significantly predicted adherence (Brady et al., 1997). In that study, 
self-efficacy and outcome expectancies were uncorrelated (r = .20, p > .05), but inspection of the 
three outcome expectancy items indicated that they might have not actually indexed beliefs that 
adhering to the hemodialysis regimen would improve their health status (e.g., “If I had a way to 
keep track of how much liquid I drink, I would be able to drink less”).  
It is possible that certain characteristics of the adherence regimen may influence the 
explanatory power of outcome versus self-efficacy expectancies. In their review of studies 
examining self-efficacy and health behaviors, Strecher, DeVallis, Becker, and Rosenstock (1986) 
concluded that self-efficacy expectancies are probably predominant when the health behavior is 
thought to lead to preferred consequences but the change is not easy to achieve. In the two 
studies examining self-efficacy and outcome expectancies discussed above (Skelly et al., 1995; 
Brady et al., 1997), the diabetes and hemodialysis regimens were characterized by considerable 
complexity or difficulty with implementation. Therefore, it is not surprising that self-efficacy 
expectancies had greater predictive power. However, the inverse of the above conclusion by 
Strecher et al. (1986) may be true for adherence to less challenging regimens, such as the 
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standard bupropion regimen which consists of two pills per day. Stated differently, it is plausible 
that outcome expectancies may be paramount when the health behavior (e.g., medication 
adherence) is not necessarily expected to lead to the desired consequences (e.g., smoking 
cessation) and the change (e.g., taking one pill twice per day) is relatively easy to make. Since 
this hypothesis is speculative, the present study examined the extent to which both self-efficacy 
and outcome expectancies predict adherence to the medication regimen. 
1.4.5 Side Effects   
Medication side effects, defined as actions of a drug that are different from its intended use 
(Barsky, Sainfort, Rogers, & Borus, 2002), are quite common among individuals taking an active 
or inactive drug. Barsky et al. (2002) differentiate two types of medication side effects: (1) 
“specific side effects are symptoms or physiological changes that result directly from the specific 
biological and pharmacological activity of the drug and tend to be dose-dependent and 
predictable,” and (2) “nonspecific side effects are symptoms or physiological changes that 
cannot be explained on the basis of the known pharmacology of the drug and are idiosyncratic 
and not dose-dependent” (p. 622). Although either type of side effects may be construed as 
indication that the medication is active and beneficial (Hitsman, Spring, Borrelli, Niaura, & 
Papandontos, 2001), it is probable that most are adverse in nature. A small subset of individuals 
consuming bupropion is expected to suffer relatively severe adverse side effects, such as 
hypertension, hives, and possibly seizure (Micromedex, 2003). In these circumstances, the health 
care provider often discontinues the regimen, and consequently, this would not be classified as 
nonadherence. Other individuals taking an active or inactive medication may experience specific 
or nonspecific side effects that are less severe and not contraindicative (Hurt et al., 1997; Jorenby 
et al., 1999; Hays et al., 2001), but are still perceived as a nuisance. It is these situations when 
individuals may decide that the benefits of the medication do not outweigh the costs of negative 
 20
side effects and in turn may voluntarily under-dose or discontinue taking the medication. As a 
smoking cessation aid, antidepressants in high doses led to increased side effect levels and higher 
incidence of dropout (Jorenby et al., 1999; Niaura et al., 2002). Side effects deterred adherence 
among adolescents taking medication for iron deficiency (Cromer, Steinberg, Gardner, Thornton, 
& Shannon, 1989) and adult women taking the infertility drug ethinylestradiol (Kruse, Eggert-
Kruse, Rampmaier, Runnebaum, & Weber, 1993). Moreover, in a randomized clinical trial 
comparing hypertensive pharmacotherapies (Preston, Materson, Reda, & Williams, 2000), 
adverse, nonspecific side effects to placebo medication led to a discontinuation rate (13%) that 
was comparable to the mean rate of six active antihypertensives (12%). Thus, it was posited that 
side effects would be inversely associated with medication adherence in the present study. 
1.4.6 Covariation among Psychosocial Predictors  
The mixed and often unreplicated findings on the associations between psychosocial variables 
and adherence in the extensive adherence literature may be attributed in part on the use of 
univariate research strategies. That is, many studies have explored the associations between 
adherence and individual psychosocial variables (e.g., DiMatteo et al., 2000). However, 
examining one psychosocial predictor in the absence of other theoretically and empirically-
related factors fails to control for related variables and therefore reduces the validity of any 
observed correlations. In other words, the overlap between many health-related psychosocial 
parameters raises questions about the extent to which the relationship between a single variable 
and adherence is confounded by the role of a third (i.e., “hidden”) variable. Although true 
experiments provide the only basis for definitive causal inferences, inferences from correlational 
research may be strengthened when confounding variables are ruled out. For example, examining 
the discrete effects of depression on adherence would negate the possibility of examining 
whether an observed correlation was accounted for in part or completely by other related 
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constructs. In the aforementioned meta-analysis on depression and adherence, DiMatteo et al. 
(2000) relied on zero-order correlations to support the conclusion that depression increased the 
risk of nonadherence among several medical regimens. However, it is plausible to hypothesize 
on a variety of conceptual grounds that a third variable, such as social support or hostility, caused 
both depression and poor adherence. Raynor, Pogue-Geile, Kamarck, McCaffery, and Manuck 
(2002) posited that, “Those who are depressed may view the world in a cynically hostile manner 
by virtue of their negative affective state. Hostile individuals may drive people away or may not 
accurately perceive others’ affiliative intentions. Individuals lacking the perception that support 
is available may be lonely and depressed as a result” (p. 191). In this vein, the Big Five factors of 
personality are thought to be conceptually distinct, but empirical evidence suggests that they are 
not orthogonal. For instance, Shadel, Niaura, Goldstein, and Abrams (2000) reported a 
significant overlap between Extraversion and Openness to Experience (r = .58) and between 
Neuroticism and Agreeableness (r = -.37). Importantly, the use of multivariate strategies, such 
multiple regression modeling, facilitates the examination of related variables by providing 
statistical information about the unique predictive utility of each variable in the context of every 
other included variable (i.e., with partial t-tests). 
It is also possible that psychosocial variables account for variance in adherence in an 
additive or interactive manner (Rozanski, Blumenthal, & Kaplan, 1999; Burns & Katkin, 1993). 
An interaction, or moderational effect, takes place when a third variable influences the direction 
and/or strength of the relation between a predictor and criterion variable (Baron & Kenny, 1986). 
An advantage of including several plausible psychosocial factors simultaneously is that the 
overall predictive utility of a block of these variables can be assessed and potentially important 
potentiation among psychosocial parameters can be tested. Although there were too many 
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possible interactions among the six aforementioned psychosocial parameters to test, a few 
notable possibilities were considered. Since individuals lacking social support may be at 
increased risk for manifesting and recovering from depression (Roberts & Gotlieb, 1997), the 
possibility that high levels of depression and low levels of social support would potentiate the 
risk of nonadherence was explored. Secondly, individuals experiencing depressive symptoms 
tend to be vulnerable to medication side effects. That is, a subset of depressed individuals may be 
“... somatically preoccupied, expect to suffer and experience discomfort, and don’t feel they 
deserve to get better” (Barsky et al., 2002, p. 625). Thus, depressed individuals experiencing 
high levels of medication side effects were expected to manifest relatively poor medication 
adherence. Thirdly, individuals experiencing a sustained change in aversive physical symptoms 
after initiating the medication regimen would be expected to manifest less favorable medication 
adherence. Stated differently, individuals who tend to experience relatively few ambient physical 
symptoms at pretreatment but then experience several negative, non-remitting medication side 
effects after starting the medication may decide to underdose or discontinue their medication. On 
the other hand, those who experience high levels of pretreatment physical symptoms may not 
attribute specific side effects to the new regimen given the “background noise” or lack of change 
from baseline. Similarly, those who experience a change in physical symptoms from 
pretreatment but then experience attenuation shortly thereafter may think that they are 
habituating to the medication (as instructed by the project nurse) or are overcoming the nicotine 
withdrawal stage. Thus, it was posited that individuals experiencing a higher number, more 
severe, and long-lasting side effects would manifest poorer medication adherence relative to 
those experiencing less aversive side effects. 
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1.4.7 Summary of Putative Psychosocial Predictors 
Although smoking cessation pharmacotherapy is increasingly prevalent, relatively little is known 
about correlates of adhering to this important health behavior. The larger health-related 
adherence literature provided some conceptual and empirical support for the predictive utility of 
several psychosocial parameters. The issues of confounding and potentiation among 
psychosocial variables provided a basis for using a multivariate approach in the present study, as 
well as motivating the choice of specific psychosocial variables and hypothesizing moderating 
patterns among some of them.  
1.5 MEASUREMENT OF ADHERENCE 
The inability to precisely measure adherence has hindered attempts to identify consistent 
predictors of this behavior. The numerous ways to assess adherence are not always accurate, and 
each one provides its own set of problems.4 For the most part, self-reported adherence is not an 
accurate measure. Whereas patient reports of poor adherence are usually reliable, reports of 
proper adherence are often inflated (Epstein & Cluss, 1982). Similarly, there is evidence that 
physicians tend to overestimate their patients’ rates of adherence (Rand & Weeks, 1998).  
More objective measurements seem to be slightly better, but they remain questionable as 
well. One of the more widely used of these objective methods is counting pills remaining in a 
patient’s prescription. This quantitative approach documents whether the proper amount of 
medication was removed from its container between clinic visits (Dunbar-Jacob et al., 1998b). 
Unfortunately, patients are able to deceive investigators by creating the impression that they 
consumed the prescribed amount (e.g., by throwing away remaining medications, sharing 
                                                 
4 For an extensive review, see Rand and Weeks (1998). 
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medications with family members, etc.), and these counts do not allow any inferences about 
whether the medication was taken on schedule or all at once (Rand & Weeks, 1998).  
The use of clinical outcomes (i.e., whether or not the patient improves) to index 
adherence is problematic in that this measure is based on the assumption that proper adherence 
will always lead to a better health outcome and that health outcomes are always a function of 
adherence (Myers & Midence, 1998). This assumption is faulty in that treatment adherence is 
only one of many factors affecting patients’ progress (e.g., individual differences in medication 
responsiveness, proper diagnosis, etc.).  
Another, more direct means to assess adherence is to measure levels of a prescribed 
medication in blood or urine. This method is the only type to verify that medications have 
actually been consumed and, as a result, have yielded somewhat more reliable estimates of 
adherence than other methods (Rand & Weeks, 1998). However, there are several problems with 
this approach, as well. There are individual differences in how patients absorb, metabolize, and 
excrete medications and, as a result, the quantity of ingested drug is unknown (Myers & 
Midence, 1998). This approach does not provide information about the temporal patterns of 
medication taking, resulting in the possibility that a patient consumes the medication directly 
before known assessments (“white-coat adherence”). Furthermore, biological verification is only 
available for a few drugs (Rand & Weeks, 1998). Not surprisingly, available evidence suggests 
that there are several limitations to therapeutic drug monitoring of bupropion (Preskorn, Fleck, & 
Schroeder, 1990). There exists wide variability in plasma levels of bupropion and its metabolites 
among patients (Preskorn & Katz, 1989). The assay used to verify these levels is technically 
complex, and results may differ as a function of the capacities of the laboratory employed. In 
addition, buproprion is not stable in plasma and, unless the sample is immediately frozen, it will 
 25
degrade (Preskorn et al., 1990). Due to the relative weaknesses of the aforementioned adherence 
measures, an indirect method, electronic event monitoring (EEM), was used as the primary 
measure of adherence in the present study. 
EEM is widely considered the best available method for measuring medication adherence 
(Dunbar-Jacob et al., 1998b; Farmer, 1999), and not surprisingly, its utilization has increased 
greatly over the past 15 years. A common attribute of electronic monitoring devices is that they 
are able to record date and time of each monitor activation via a microprocessor chip (Dunbar-
Jacob et al., 1998b). These are the only type of data that provide information about the temporal 
patterning of medication taking. Such devices have been developed for a range of medication 
adherence behaviors, including opening a pill bottle or box, removal of tablets from a blister 
pack, releasing eye drops, and discharging inhaled medications (Rand & Weeks, 1998). The 
device used in the present study was the Medication Event Monitoring System (MEMS, 
AARDEX Ltd, Zug, Switzerland). The MEMS cap contains a microprocessor that electronically 
logs each instance the medication bottle is opened and records the date, time, and duration of 
opening. In turn, these data are downloaded onto a personal computer for subsequent analysis 
(Rand & Weeks, 1998). Importantly, efforts to mislead the investigators or clinicians by patients 
(e.g., by repeatedly opening MEMS cap in a short period of time) are identified and ruled out in 
the editing process (Dunbar-Jacob et al., 1998b). 
Although the MEMS and other electronic devices do not provide actual data on 
medication ingestion, the activation of these monitors serves as a proxy of consumption. 
Therefore, it is still possible that patients do not actually take the medication when the cap is 
opened. For instance, this approach would be inaccurate if patients took the medication from the 
MEMS bottle and stored it in another bottle. This would result in the lower estimation of pill 
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consumption (Dunbar-Jacob et al., 1998b). Nonetheless, as the monitors log each cap opening, 
“patients would need to exert considerable, deliberate effort to fool the system; that is, they 
would have to activate the medication monitor at each correct administration time. This is 
unlikely…” (Dunbar-Jacob et al., 1998b, p. 99). In the present study, participants were instructed 
to use only the MEMS bottle to hold their study medication and to consume the prescribed 
amount directly upon opening the cap. 
Dunbar-Jacob and colleagues (1998b) reviewed evidence comparing the accuracy of 
adherence measures, including self-report, pill counts, and EEM. In short, EEM usually offers a 
lower estimate of adherence in relation to other measures, particularly self-report. The reviewers 
concluded that EEM measures are the most accurate, and other measures may overestimate 
adherence, with potentially undesirable consequences. In addition, Dunbar-Jacob et al. (1998b) 
discussed how measurement of adherence has a major influence on the significance of 
psychosocial predictors of adherence. In an earlier study, Dunbar-Jacob and her colleagues (as 
cited in Dunbar-Jacob et al., 1998b) compared a set of potential predictive factors across three 
measurement methods: EEM, 24-hour recall, and an interview reviewing the previous month. 
When using the 24-hour recall and the interview, the psychosocial characteristics did not predict 
adherence, but social support and pain significantly predicted adherence measured with EEM. 
Therefore, the inconsistent results in the prediction of adherence across studies may be a function 
of diverging methods of assessing adherence. Dunbar-Jacob et al. (1998b) suggested that “the 
electronic event monitors cause us to reexamine what we know about predictors of adherence. 
Our data suggest that many of the findings on adherence predictors may be related to the 
measurement method rather than the actual behavior… Clearly, more work is indicated in 
separating out the predictors of adherence behavior and the correlates of each measurement 
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method” (p. 110). For these reasons, evaluating predictors of EEM-measured medication 
adherence was a relative strength of this study. 
In addition to the wide array of methods for assessing medication adherence, there are 
multiple ways of defining medication-taking behavior. The most basic dimension of adherence 
may be considered medication “completion” versus “non-completion.” In the present study, 
medication completion was defined as manifesting greater than or equal to 14 days of correct 
intake. That is, participants who failed to take any medication or who discontinued medication 
within two weeks of initiating the regimen were classified as non-completers. The rationale for 
establishing this threshold was based on following reasons: (1) it is possible that psychosocial 
factors associated with failure to take a minimum amount of mediation may differ from factors 
associated with future discontinuation or deviation from the prescribed regimen; (2) the intent to 
treat approach of classifying smoking relapse dictates that non-completers are classified as 
having relapsed (Hughes et al., 2003), and as a result, an association between medication 
adherence (including non-completers) and smoking relapse would be highly conflated; and (3) 
evidence suggests that medication adherence during the first several weeks of the regimen is one 
of the strongest predictors of long-term health outcome, e.g., initial adherence to an anti-
cholesterolemia regimen predicted five-year mortality in the Lipid Research Clinics Coronary 
Primary Prevention Trial (Dunbar-Jacob et al., 1998a). 
Among completers, medication adherence is often operationalized by the quantity of 
medication-taking events. This type of adherence definition reflects the total amount of 
medication taken over a cumulative time span (Martin, Bowen, Dunbar-Jacob, & Perri, 2000). 
The typical manner of defining adherence in this manner is by dividing the number of dose self-
administrations by the prescribed number of doses during the specific time period and 
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multiplying by 100%. This statistic is referred to as the “percentage of prescribed administrations 
taken” (Sereika & Dunbar-Jacob, 2001). Although this index provides gross information about 
whether a patient took too much or too little medication during the regimen period, it does not 
include information about the timing of medication intake. As a result, a patient who opened the 
MEMS cap multiple times in one day but skipped several days may still be considered a good 
adherer (Sereika & Dunbar-Jacob, 2001). Moreover, adherence definitions based solely on 
quantity of administrations over an extended period of time fail to allow for the possibility that 
adherence may change over the course of a health-related behavior or chronic disease regimen. 
For instance, Myers and Branthwaite (1992) found that patients typically terminated treatment 
altogether at the beginning of a regimen, became more casual about the treatment during the 
middle and often forget, and began varying the dosage themselves as the regimen moved into a 
long-term maintenance phase.  
EEM-assessed medication adherence also permits the operationalization of several other 
distinct types of nonadherence, including errors of omission, dosage, or timing. Since the time of 
cap openings/closings is recorded in real time, information about the timing of events between 
(e.g., two pills per day) and/or within (e.g., two pills in a day separated by a lag of 8-14 hours) 
days may be compared against the actual medication prescription. One such summary index is 
referred to as the “percentage of days with the prescribed number of administrations” or 
“percentage of days with correct intake” (Sereika & Dunbar-Jacob, 2001). With this measure, a 
patient is dichotomously classified as either adherent or nonadherent each day as a function of 
whether he or she took the correct number of pills that day. The sum of total adherent days is 
then divided by the total days in the regimen and is multiplied by 100% to arrive at this summary 
measure of correct intake. Although this statistic does not provide information about timing of 
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pill consumption within the day, it does provide substantially more temporal information than the 
aforementioned measure of “percentage of prescribed administrations taken.”  
An extension of the measure of correct daily intake is the “percentage of days with the 
correct number of administrations and timing” (Sereika & Dunbar-Jacob, 2001). Specifically, in 
addition to providing information about correct number medication-taking behaviors in a day, it 
also takes into consideration the relative timing of proximate medication doses. The 
determination of correct timing between doses within a given day is inexact, but Sereika and 
Dunbar-Jacob (2001) suggested, “a ‘near’ optimal interval [should be] based on the prescribed 
daily frequency of doses with a clinically reasonable window of medication-taking about the 
targeted time of administration. A standard convention is to set the dosing window within 20% to 
25% of the prescribed interval...” (p. 147). Since the half-life of 150mg sustained release 
bupropion is 14 hours (Micromedex, 2003), a window of 8 to 14 hours (11 hours ± 27.3%) was 
established for the present study. This index may provide a relatively conservative index of 
medication adherence in that there is minimal forgiveness for minor deviations from the exact 
medication regimen. 
It is important to note that the two indices incorporating timing of medication events, the 
“percentage of days with the prescribed number of administrations” and “percentage of days 
with the correct number of administrations and timing,” do not provide information about days 
of underdosings, overdosings, and drug holidays (i.e., one or more consecutive days of no 
medication-taking events; Sereika & Dunbar-Jacob, 2001). Fortunately, EEM-measured 
adherence data allows for the operationalization of such indices.  
Conducting multiple analyses with each summary measure of adherence as a criterion 
would have led to an unacceptably high experimentwise Type I error rate. Therefore, the pros 
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and cons of several candidate indices were weighed before deciding on the summary index to be 
used in the primary analyses. As mentioned previously, the “percentage of prescribed 
administrations taken” index may overestimate medication adherence because the timing of dose 
administrations is not incorporated into its definition. On the other hand, “percentage of days 
with the correct number of administrations and timing” index may underestimate an adequate 
level of medication adherence because both timing across and within days are incorporated into 
its definition. The of “percentage of prescribed administrations taken” index may be the optimal 
index of medication adherence because it evaluates correct dosage for each day of the regimen 
but does not incorporate a potentially conservative inter-dose interval within each day. Thus, 
although all of the previously described summary indices were used to describe the rates of 
medication adherence, the latter one was chosen as the summary measure for use in the primary 
analyses on the predictors and consequences of medication adherence.  
To recapitulate, the use of EEM to assess medication adherence and the inclusion of 
multiple summary measures of medication-taking behavior were expected to provide a relatively 
accurate measure of medication consumption, provide a broader depiction of multifaceted 
medication-taking behavior, and possibly provide unique information in the prediction of 
medication adherence. Importantly, the use of the percentage of days with the correct intake 
index over an extended period allowed for the break down of the larger study period (90 days) 
into shorter periods (of 30 days). Consistent with previous research (e.g., Myers and 
Branthwaite, 1992), it was expected that sample averages would decrease over each of these 30-
day periods. 
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1.6 SEQUELAE OF ADHERENCE 
Patients who manifest better adherence are thought to benefit more from medical treatments than 
patients who manifest poorer adherence. It is widely assumed by many clinical researchers and 
practitioners that resulting positive health outcomes are a function of adherence to a medication 
with an active, specific pharmacological effect. The following sections will explore the validity 
of this assumption in the context of smoking cessation and other health behavior and disease 
regimens. 
1.6.1 Smoking Cessation 
A nicotine patch intervention study provides a test of this assumption. Killen, Fortmann, Davis, 
and Varady (1997) reported that among high adherers to a nicotine patch regimen, 70% were 
abstinent at 100 days and 42% of high adherers were abstinent at 200 days, respectively. In 
contrast, 32% and 20% of poor adherers were abstinent at 100 and 200 days, respectively. 
Importantly, the assumption that adherence only to the active nicotine patch led to increased 
smoking cessation rates would have led to an erroneous conclusion. This is because adherence to 
the patch regimen, independent of active or placebo condition, had an important effect on 
relapse. Killen et al. (1997) used Cox proportion hazards analysis to examine time to relapse, 
with treatment condition (nicotine or placebo patch), adherence with counseling treatment 
manual, and adherence with patch regimen included as independent variables. At 2 months, 
patch adherence status and patch treatment condition were significant predictors in the model, 
but at 6 and 12 months, patch adherence status was the only significant predictor. The Killen et 
al. (1997) finding that adherence to patch regimen had a direct effect on smoking cessation is 
consistent with a small but growing body of research supporting the main effect of medication 
adherence on a variety of health outcomes, independent of whether the patient is taking the 
active drug or placebo. 
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In order to examine the main effect of adherence, independent of active medication, the 
reporting of adherence behavior in both active medication and placebo groups is necessary. A 
recent report comparing the effects of fluoxetine versus placebo on smoking cessation 
demonstrates why this information is important. Hitsman et al. (2001) investigated the influence 
of serum fluoxetine levels (i.e., an index of adherence to an active medication) on adherence to 
behavioral smoking cessation treatment and smoking cessation outcome. Results showed that 
individuals with higher levels of fluoxetine were less likely to drop out of behavioral treatment 
and more likely to maintain prolonged abstinence over 10 weeks. The limited utility of indexing 
medication adherence solely via drug levels in plasma is underscored by the lack of information 
about placebo regimen adherence. The authors pointed out that, as a result, it is impossible to 
rule out that fluoxetine levels were a proxy for a general tendency to adhere to treatment, which 
may have led to enhanced behavior therapy adherence and prolonged smoking abstinence. 
Unfortunately, with the exception of the Killen et al. study (1997), no studies in the smoking 
cessation literature have presented information on adherence to active and placebo medications. 
1.6.2 Other Health Behavior and Disease Regimens 
Epstein (1984) identified six experimental studies in the broader health outcomes literature in 
which active pharmacological agents were compared against placebos. The health outcomes 
included cardiovascular mortality, weight loss, alcohol abstinence, psychosis relapse, and fever 
or infection among cancer patients. An adherence vs. nonadherence dichotomization was made 
either by the original authors or by Epstein. When comparing the effect of the medication against 
the placebo, only half of the studies reported a significant improvement of the medication groups 
(the rest were null). However, a main effect of adherence was found in five of the six studies. It 
is important to note that, in order to demonstrate this effect, patients who were adherent in both 
the active medication and placebo groups were required to achieve better health outcomes.  
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Several pertinent studies were published after Epstein’s (1984) review. For example, 
adherence data was available for 2175 post-myocardial infarction (MI) patients who participated 
in the β-Blocker Heart Attack Trial (BHAT; Horwitz et al., 1990). Patients who were randomly 
assigned to propranolol or placebo were assessed at one year. Adherence was assessed with pill 
counts. Even after controlling for MI severity, patients who were classified as poor adherers 
(took less than or equal to 75% of their medication) were 2.6 times more likely than good 
adherers to die within the follow-up year. Analysis of the propranolol group revealed that the 
mortality rate was 4.2% for poor adherers and 1.4% for good adherers. In the placebo group, the 
mortality rates were 7.0% and 3.0% for poor and good adherers, respectively. There was no 
significant difference between treatment groups on mortality. Horwitz et al. (1990) used a series 
of multiple regression models to determine whether sociodemographic variables, psychosocial 
variables (i.e., life stress and social isolation), and smoking accounted for the main effect of 
adherence. Some of these predictors were related to mortality, but the main effect of adherence 
could not be explained by these variables. 
McDermott, Schmitt, and Wallner (1997) reviewed several studies examining the effects 
of medication adherence on cardiovascular morbidity and mortality among patients with or at 
risk for coronary artery disease and congestive heart failure. Twelve studies were identified that 
compared hospitalization rates and mortality between adherers and nonadherers. Seven studies 
found that adhering to medication positively affected health outcomes, and three studies showed 
that adhering to placebo regimens was predictive of positive outcomes. More recently, Irvine et 
al. (1999) examined the association between adherence and mortality among 1141 patients in the 
randomized, double-blind Canadian Amiodarone Myocardial Infarction Arrhythmia Trial 
(CAMIAT). Results indicated that poor adherence to either amiodarone or placebo was 
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associated with increased risk for sudden cardiac death, total cardiac mortality, and all-cause 
mortality. Again, no differences were found between treatment groups on mortality, and several 
medical, demographic, or psychosocial characteristics were not able to account satisfactorily for 
the main effect of adherence on outcome.     
These studies provide convincing evidence for the main effect of adhering to medical 
regimens on a range of treatment outcomes, independent of whether the patient is taking the 
active study medication or placebo. Taken together, these findings are promising, but additional 
research with a variety of populations, medications, and health outcomes is needed to add 
reliability and generalizability to this effect. Thus, one of the goals of the present study was to 
examine the main effect of adherence to the study medication (i.e., independent of bupropion or 
placebo status) on smoking cessation among women who were engaged in smoking cessation 
clinical trial. Interestingly, many of the aforementioned studies did not consistently demonstrate 
that medication adherence interacted with the level of medication (active or placebo) to produce 
positive treatment results. These mixed results may be due to a reduced effect size of the 
specific, pharmacological agent. This explanation is consistent with findings from a recent meta-
analysis by Kirsch and Sapirstein (1999) indicating that approximately 25% of the response to 
antidepressant medications is due to the administration of an active medication, 50% due to a 
placebo effect, and the remaining 25% due to other nonspecific factors. Thus, the assumption 
that adhering to medical regimens enhances specific, active pharmacological effects requires 
further empirical validation. 
1.6.3 Main Effect of Adherence: Possible Mechanisms  
The vast majority of studies in this area have not focused on adherence as an independent 
predictor of health outcome. These randomized, double-blind studies were designed to compare 
medication versus placebo effects (Epstein, 1984). In fact, the observation of the adherence 
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effect in the Coronary Drug Project (1980), one of the first studies to report this finding, was 
apparently discovered serendipitously. For this reason, most of these studies did not discuss or 
include measures of possible mechanisms underlying the main effect of adherence. As discussed 
above, the BHAT (Horwitz et al., 1990) and CAMIAT (Irvine et al., 1999) are two exceptions, 
but none of the medical, demographic, or psychosocial characteristics assessed in these trials 
accounted for the main effect of adherence on mortality. Furthermore, as with the literature on 
predictors of adherence, all of the studies examining adherence, health outcomes, and potential 
mechanisms were observational. For these reasons, the mechanisms underlying the nonspecific 
effect of adherence are presently unknown. 
Although there are no published findings indicating what active ingredients account for 
the main effect of adherence on health outcome, several alternative explanations exist. The main 
effect of adhering to placebo on health-related behavior change or clinical status suggests that 
factors other than just the effectiveness of the specific, pharmacological agent are functioning. 
The active, specific components of a medication may be maximized by good adherence, but such 
behavior may also activate nonspecific effects that lead to treatment success. Therefore, it has 
been suggested that the ingredients driving the nonspecific adherence effect are analogous to the 
ingredients underlying the placebo effect (Czajkowski, Chesney, & Smith, 1998). As the placebo 
effect is believed to be a function of nonspecific components of treatment, Czajkowski et al. 
(1998) posited that positive outcome expectancies and social support are the active ingredients of 
the main effect of adherence. On the other hand, it is possible that particular characteristics of 
good treatment adherers predispose them to profit more from nonspecific aspects of treatment 
(Czajkowski et al., 1998; Horwitz & Horwitz, 1993). For instance, conscientious individuals, 
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who may be more apt to adhere to treatment, may seek out more social support from friends and 
family, which in turn leads to better health outcomes.  
Thus, another objective of including several promising psychosocial variables in the 
present study was to help to characterize the active ingredients of the hypothesized relationship 
between adherence to the medication regimen and the health outcome, smoking cessation. 
Exploratory regression analyses were used to determine whether psychosocial parameters were 
associated with both medication adherence and prolonged smoking abstinence. Adjustment for 
such parameters factors in subsequent hierarchical regression analyses provided information 
about whether the main effect of adherence could be accounted by one or more of these 
psychosocial characteristics.  
1.7 STUDY AIMS 
The aims of this study were to examine rates, predictors, and sequelae of adherence to a smoking 
cessation medication regimen among weight-concerned women engaged in a smoking cessation 
intervention study. There is little empirical or conceptual research on adherence to smoking 
cessation pharmacotherapy, and as such, this exploratory study provided the first extensive look 
at adherence to a regimen of bupropion versus placebo. The following research questions and 
hypotheses were addressed: 
Question 1.  What are the rates of adherence to a medication regimen among a sample of 
female weight-concerned smokers participating in a smoking cessation clinical trial?  
Hypothesis 1a. The primary composite index of medication adherence, which emphasizes 
the correct number of daily doses, was expected to be suboptimal over the 90-day period and was 
also expected to decrease over each successive 30-day period.  
 37
Hypothesis 1b. Medication adherence was expected to progressively decrease when 
operationalized as (a) percentage of prescribed doses taken over the study period, (b) percentage 
of days with the correct number of doses taken, and (c) percentage of days with the correct 
number of doses taken and correct timing between doses, respectively. 
Question 2.  To what extent do individual differences in depressive symptoms, 
agreeableness, conscientiousness, social support, medication side effects, and medication 
efficacy and outcome expectancies predict adherence to the medication regimen? 
Hypothesis 2.  Higher levels of depressive symptoms and medication side effects were 
expected to be negatively associated with medication adherence, whereas agreeableness, 
conscientiousness, social support and optimistic medication efficacy and outcome expectancies 
were expected to be positively associated with medication adherence. An interaction between 
depressive symptoms and medication side effects was expected to significantly predict 
medication adherence. Individuals with high levels of depressive symptoms and medication side 
effects were expected to be more likely to manifest poorer medication adherence relative to 
individuals with low levels of depressive symptoms or medication side effects. Moreover, 
individuals experiencing a sustained change in side effects from basal levels were expected to 
manifest poorer adherence than those whose symptoms did not change from pretreatment levels 
or remitted over time. 
Question 3.  To what extent does adherence to the medication regimen predict smoking 
abstinence, independent of medication treatment?  
Hypothesis 3.  High levels of medication adherence were expected to be positively 
associated with prolonged smoking abstinence and point prevalence abstinence rates over time. 
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2 METHOD 
 
2.1 PARTICIPANTS 
One hundred-and-fifty-five adult women participated in the smoking cessation program.5 
Participants were recruited primarily via newspaper, bus, and television advertisements to take 
part in a smoking cessation treatment program designed to assess counseling and 
pharmacological approaches to assisting weight-concerned women quit smoking. All participants 
in the smoking cessation program smoked at least 10 cigarettes per day for at least one year and 
reported considerable concerns about post-cessation weight gain. All women were required to be 
healthy, not pregnant, lactating or interested in becoming pregnant during the clinical trial, and 
employing suitable birth control. Individuals with current Axis I psychiatric disorders were 
ineligible. Individuals with current or recent (in the past year) in-patient hospitalization for 
psychiatric, drug, or major medical problems were also ineligible. Other exclusionary criteria 
included history of seizure, serious head injury, and current or historical eating disorders. Lastly, 
women were also excluded if they were currently taking medications that may lower the seizure 
threshold, psychotropic medications, or nicotine replacement therapy.  
Participants were initially screened over the telephone for inclusion/exclusion criteria. 
Next, participants attended an information session at which signed informed consent was 
                                                 
5 The present study was part of a larger clinical trial that will ultimately recruit 450 participants over a four-year 
period. The larger trial has a longer period of intervention (26 weeks) and follow-up assessment (52 weeks). 
Procedures from the larger clinical trial that are beyond the scope of this “sub-study” are not presented. 
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obtained and screening information was documented. Participants were then scheduled for 
individual telephone appointments for the administration of the Structured Clinical Interview for 
DSM-IV, Version 2 (SCID; First, Spitzer, Gibbon, & Williams, 1998). Finally, individuals were 
scheduled for a physical examination to make sure that health-related eligibility criteria were 
met. The study was approved by the University of Pittsburgh Biomedical Institutional Review 
Board. 
The age range was 19 to 62 years old, with a mean age of 43 (SD = 9.7 years). 
Participants were 87% Caucasian, 12% African-American, and 1% Pacific Islander/Native 
Hawaiian. Nearly all participants (98.7%) completed high school and 33.5% completed at least a 
four-year college degree. On a Likert scale ranging from 0 (not at all) to 100 (extremely), the 
mean rating of participants’ pretreatment desire to quit smoking was 85.6 (SD = 14.5) and the 
mean concern about gaining weight after quitting smoking was 73.50 (SD = 24.3). Additional 
descriptive characteristics of the participants are displayed in Table 1. 
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Table 1 
 
Participant Characteristics 
 
             
 
Characteristic     Mean   Standard Deviation   
             
 
Age (years; N = 155)    43.19   9.69 
 
Years of smoking (N = 150)   25.07   10.18 
 
Cigarettes/day (N = 150)   20.89   8.23    
 
Fagerstrom tolerance (0-10; N = 150) 5.11   2.08 
 
Body Mass Index (N = 155)   27.32   5.45 
             
 
Characteristic        Percentage 
             
 
Race (N = 155) 
 Caucasian       87.1   
 African-American      12.3 
 Native Hawaiian or other Pacific Islander   0.6 
 
Highest education level (N = 150) 
 Grade school or some high school    1.3 
 High school graduate      13.5 
 Some college/technical school    49.0 
 Four-year college graduate     24.5 
 Post-graduate degree      9.0 
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2.2 PROCEDURE 
2.2.1 Research Design  
All participants were randomized into a larger double-blinded RCT examining the effects of 
medication (bupropion versus placebo) and counseling (weight-focused CBT versus standard 
support) on smoking cessation. The psychosocial treatments were not designed to influence 
medication adherence differentially (see Perkins et al., 2001). Given that medication adherence 
was observed over time but not manipulated, the research design for the present study was 
longitudinal and passive-observational (Kazdin, 1992). 
2.2.2 Pharmacotherapy 
Participants were randomly assigned to receive bupropion or an identical appearing placebo at 
Week 2 of treatment (six days before the quit date). Participants took the study drug for the 
remaining 12 weeks of treatment. All women were directed to take one 150 mg capsule daily for 
the first three days and then two 150 mg capsules each day for the remainder of the study. A 300 
mg daily dose was chosen based on safety and published smoking cessation findings (e.g., Glaxo 
Wellcome Inc., 1999; Hurt et al., 1997). All participants were seen individually by a project 
nurse five times over the 12-week period. These clinic visits were scheduled at Weeks 2, 3, 5, 8, 
and 10. During each visit, the project nurse completed a Medication Management Form, which 
included information about medication side effects. Treatment was free, but a small, refundable 
deposit of $25 was requested from participants to increase counseling session attendance. 
2.3 MEASURES 
The primary measures of depression, personality, social support, and self-efficacy and outcome 
medication expectancies were assessed at the pretreatment information session. Medication side 
effects were assessed at Weeks 2 (pretreatment), 3, and 5 nurse visits. Secondary measures of 
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depression, social support, and medication outcome expectancies were collected at Week 6. 
Unless otherwise specified, all subsequent references to these psychosocial parameters pertain to 
baseline measurements. 
2.3.1 Depression  
The BDI (Beck et al., 1961) is a 21-item self-report scale that includes descriptions of typical 
symptoms of depression (i.e., fatigue, hypochondriasis, insomnia, pessimism, sadness, self-
dislike, and suicidal ideation) experienced over the past two weeks. The BDI has been used 
extensively in both clinical and nonclinical populations as a measure of depressive 
symptomatology (Beck, Steer, & Garbin, 1988). Test-retest reliability of the BDI ranges from .62 
(4 months) to .90 (2 weeks) in nonpsychiatric undergraduate students (Beck et al., 1988). The 
BDI has an internal consistency of 0.86 for psychiatric patients and .81 for nonpsychiatric 
individuals (Beck et al., 1988).  
2.3.2 Personality 
The personality factors of conscientiousness and agreeableness were assessed with the NEO-FFI 
(Costa & McCrae, 1992). The NEO-FFI is a short-form measure (60 items) of the NEO-PI-R 
(Costa & McCrae, 1992), which indexes the Big Five Personality factors of neuroticism, 
conscientiousness, extraversion, openness to experience, and agreeableness. The 
conscientiousness scale of the NEO-FFI is highly associated with the conscientiousness scale of 
the longer version, NEO-PI-R (r = .87) and internal consistency is high (α = .81; Costa & 
McCrae, 1992). Similarly, the agreeableness scale of the NEO-FFI is highly associated with the 
agreeableness scale of the NEO-PI-R (r = .77); internal consistency is acceptable (α = .68; Costa 
& McCrae, 1992). 
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2.3.3 Social Support  
The ISEL (Cohen et al., 1985) is a 40-item measure of perceived availability of specific forms of 
social support, including appraisal, belonging, self-esteem, and tangible support. Internal 
consistency reliabilities for the ISEL range from .88 to .90 (Cohen et al., 1985). Cohen et al. 
(1985) reported adequate test-retest reliability of the ISEL, with a six-month reliability of .74. 
Given that the four types of support are highly intercorrelated (Sarason, Shearin, Pierce, & 
Sarason, 1987) and confirmatory factor analysis results are consistent with the existence of an 
underlying second-order general factor of support (Brookings & Bolton, 1988), the total ISEL 
score was used in this study. 
2.3.4 Expectancies 
There have been few attempts to investigate pharmacotherapy-related efficacy and outcome 
expectancies in health domains, and no published works on expectancies for smoking cessation 
medications. For this reason, a measure indexing medication outcome (items 1-13) and self-
efficacy (items 14-24) expectancies was developed for this study. The Study Medication 
Expectancies Questionnaire (SMEQ; see Appendix A) was loosely based on several relevant 
sources, including two previously used measures assessing outcome expectancies of arthritis 
medication, the Perceived Therapeutic Efficacy Scale (Dunbar-Jacob et al., 1993), and self-
efficacy to adhere to an HIV+ medication regimen, the Treatment Self-Efficacy scale (Catz et al., 
2000; S.L. Catz, personal communication, July 27, 2000). In addition, outcome expectancy items 
were developed to assess several response expectancies (e.g., cravings, weight control, etc.), the 
type of outcome expectancy most commonly assessed in smoking research (Brandon et al., 
1999). Many of the specific response expectancies were derived from the DSM-IV (American 
Psychiatric Association, 1994) criteria for nicotine withdrawal.  
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Likewise, self-efficacy items were based in part on others’ works. These items were 
designed to assess an individual’s confidence in her ability to take the study medication in 
contexts of varying difficulty, which is consistent with Bandura’s (1997) suggestions on how to 
develop a self-efficacy questionnaire. Although several high-risk situations were based on those 
from Catz et al.’s (2000) questionnaire on HIV medication adherence, several others were culled 
from Gwaltney et al.’s (2001) smoking cessation-specific Relapse Situation Efficacy 
Questionnaire. 
Reliability analyses indicated that the medication outcome expectancies subscale (α = 
.89), the medication self-efficacy expectancies subscale (α = .88), and the entire SMEQ (α = .88) 
had adequate internal consistencies. As expected, the medication outcome and self-efficacy sub-
scales were moderately and positively correlated (r = .24, p = .004, N = 147). Taken together, the 
strong internal consistencies and the relatively minimal shared variance (R2 = 5.8%) of the two 
subscales provided support for the psychometric adequacy of this measure.  
2.3.5 Side Effects 
Medication side effects were assessed at Weeks 2, 3, and 5 with an investigator-designed 38-item 
questionnaire based on symptom lists used in Federal Drug Administration drug trials. For Week 
2, or pretreatment, participants were asked to check off any problems that they had experienced 
in the previous week. For Weeks 3 and 5, participants were asked to check off any symptoms 
that they had experienced since their previous medication check-up/refill visit. Then the study 
nurse asked participants to rate each positively endorsed symptom on a 1-6 Likert scale, with 1 = 
very mild or only happened once and was not bothersome, 4 = present on more than half the days 
or somewhat bothersome in intensity, and 6 = it happened every day or was very bothersome. 
Since the Week 2 symptoms were assessed prior to initiating the medication regimen, this 
information more accurately indexes ambient physical symptoms. Still, for the sake of 
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consistency, pretreatment physical symptoms are referred to as Week 2 side effects throughout 
the remainder of this report. 
2.3.6 Nicotine Dependence  
Participants completed the Fagerstrom Tolerance Questionnaire (Fagertrom, 1978) at 
pretreatment. This eight-question measure is designed to assess nicotine dependence on a scale 
ranging from 0 (no dependence) to 11 (high dependence).  
2.3.7 Medication Adherence  
Adherence to the medication regimen was assessed with the Medication Event Management 
System (MEMS) Smart Cap (AARDEX Ltd, Zug, Switzerland). The MEMS consists of a 
medication bottle that contains a pressure-activated microprocessor in the cap. This 
microprocessor automatically records each opening of the medication bottle (i.e., an event), 
providing the number of times opened each day and the hours since the bottle was last opened. 
The MEMS Smart Caps were also equipped with a digital display indicating to participants in 
real-time the number of daily cap openings and time elapsed since the previous opening. The 
digital display was pre-programmed to reset automatically each day at 3AM. Participants were 
instructed to use this information to facilitate proper adherence and were also told that these data 
would be used for research purposes. Data from the microprocessor were downloaded to a 
personal computer for later analysis at Weeks 3, 5, 10, and 14. The total number of doses 
prescribed during the 12-week period was 177, although this number was smaller for some 
participants if their dosage was reduced by the project physician.  
Consistent with the recommendations of Sereika and Dunbar-Jacob (2001), six summary 
measures were used to explain the EEM data. Each index was computed for the entire 90-day 
period as well as for the three 30-day periods. Specifically, the adherence summaries measured 
were: (1) the percentage of prescribed doses taken during the time periods, (2) the percentage of 
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days with the correct number of doses, (3) the percentage of drug holidays (i.e., no doses taken 
for one or more consecutive days), (4) the percentage of days with underdosing (i.e., less than the 
correct number of doses was recorded), (5) the percentage of days with overdosing (i.e., more 
than the correct number of doses was recorded), and (6) the percentage of days with the correct 
number of doses and correct timing between doses.  
2.3.8 Smoking Cessation 
Smoking status was assessed at each of the 12 behavior therapy sessions. There was one meeting 
during the 1st week of treatment, two meetings each during the 2nd and 3rd weeks (immediately 
prior to and after the smoking quit date), one meeting during the 4th, 5th, and 6th weeks, and three 
more bi-weekly meetings during the 8th, 10th, 12th and 14th weeks. Using an intent to treat 
approach, any participant who failed to maintain regular attendance at study visits was 
considered to have relapsed (Hughes et al., 2003).  
All smoking cessation definitions were based on recent recommendations from the 
Society of Research on Nicotine and Tobacco (SRNT) subcommittee on abstinence measures 
(Hughes et al., 2003). The efficacy of smoking cessation was evaluated with rates of prolonged 
abstinence over the 12-week period. Relapse was defined as (1) seven consecutive days of 
smoking, or (2) smoking at least once each week on two consecutive weeks, including an initial 
two-week grace period. The two-week grace period meant that any smoking during the first 14 
days after the quit date was not considered a relapse. According to SRNT guidelines, the 
rationale for this grace period is twofold: (1) a subset of individuals who a few cigarettes after 
quitting will go on to maintain permanent abstinence, and (2) the effects of treatment may not be 
fully effective until at least a few weeks of therapy (Hughes et al., 2003). Only those participants 
who self-reported abstinence and provided biochemical verification at each visit were classified 
as manifesting prolonged abstinence. Biochemical verification of abstinence included expired-air 
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carbon monoxide concentrations below eight parts per million (ppm) Although perfect 
attendance was not expected, participants were nonetheless required to provide negative CO 
measurements at ≥ 75% of the eight post-quit sessions in order to be considered abstinent.  
Point prevalence abstinence rates were also computed at Weeks 6, 10, and 12 as 
secondary outcome measures. Point prevalence abstinence rates were defined more 
conservatively than prolonged abstinence in that no smoking at all was permitted during the day 
of the assessment as well as the previous seven days. Although SRNT subcommittee 
recommended the inclusion of survival analysis as a nontraditional measure of smoking relapse 
(Hughes et al., 2003), the relatively short follow-up in the present study (90 days) was not of 
sufficient duration to provide clinically meaningful information. For example, a difference of 30-
50 days in time to relapse between individuals with “good” versus “poor” adherence rates may 
be statistically significant, but such a small difference would be relatively unimportant given that 
prolonged abstinence of at least one year is the hallmark of successfully quitting smoking. For 
this reason, survival analyses were not included in this report.  
2.4 DATA ANALYSIS 
2.4.1 Statistical Analysis Plan 
After descriptive statistics were computed, hierarchical multiple linear regression model building 
was performed to examine the hypothesized predictors of medication adherence. The procedure 
of automatic stepwise selection was used to ascertain the best subset of predictor variables. 
Although exploratory studies typically utilize a relatively liberal alpha level (i.e., entry criterion 
of .20 and elimination criterion of .25; Tabachnick & Fidell, 1996) to reduce Type II error rate, 
the entry and elimination criteria were set conservatively at .05 and .10, respectively. These 
criteria were chosen to minimize the experiment-wise Type I error rate that could be inflated due 
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to multiple analyses. A preliminary multiple linear regression model was fit to determine 
whether potentially confounding variables should be entered in the final model. Specifically, 
medication group, counseling group, age, race, education status, and Fagerstrom tolerance scores 
were entered simultaneously as predictors and medication adherence was set as the criterion of 
this regression equation. Dichotomous variables, including medication and counseling groups, 
race, and education status, were dummy coded. Then multiple regression model building was 
conducted with 90-day medication adherence entered as the dependent variable and the pool of 
predictor variables entered in three steps. Any potentially confounding variables found to be 
associated with medication adherence in the prior analysis were entered in the first step of the 
regression equation. Main effect terms of BDI, agreeableness, conscientiousness, ISEL, 
medication efficacy expectancies, medication outcome expectancies, and Weeks 2, 3 and 5 side 
effects were entered in the second step. A priori designated interaction effects comprised the 
third step, including a two-way interaction of BDI-by-Week 5 side effects and a three-way 
interaction of Week 2-by-Week 3-by-Week 5 side effects. The overall model fit was examined 
via an F-test and the significance of individual predictors was evaluated with partial t-tests and 
R2 change values. The reported betas are the standardized regression coefficients for the final 
model. Several diagnostic procedures were used to examine and verify assumptions of linear 
regression model building (see Appendix B for procedural details). 
Next, multiple logistic regression analysis was performed to examine the main effect of 
medication adherence on smoking cessation. The dichotomous outcome of prolonged smoking 
abstinence was entered as the criterion variable and 90-day medication adherence was entered as 
the predictor variable. The same potentially confounding variables assessed with linear 
regression model building were examined for their association with smoking cessation and, if 
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significant, were entered as covariates in the logistic model. The model χ2 test, the Hosmer-
Lemeshow goodness-of-fit index, and R2L (i.e., a hand-calculated coefficient of determination 
analogous to R2 in linear regression; Menard, 2002) were used to evaluate the overall fit of the 
model, and the likelihood ratio test was used to assess the significance of including a predictor to 
the overall model. See Appendix B for diagnostic procedures used for examining and verifying 
logistic regression assumptions.  
Tests for statistical mediation and moderation were conducted in cases where a 
psychosocial variable was associated with both medication adherence and prolonged smoking 
abstinence. A mediator variable is responsible partly or completely for the process by which one 
variable significantly influences another (Baron & Kenny, 1986). When testing for mediational 
effects, the following criteria were assessed for statistical significance (p < .05): (1) the predictor 
was significantly associated with the criterion, (2) the predictor was significantly associated with 
the mediator, and (3) after controlling for the predictor, the mediator was significantly associated 
with the criterion (Baron & Kenny, 1986). If these criteria were upheld, then a statistical test was 
conducted to determine whether the association between the predictor and criterion was 
significantly attenuated after controlling for the mediator (Holmbeck, 2002). A moderator 
variable influences how a predictor is associated with a criterion. A moderational effect is also 
commonly referred to as a statistical interaction, such that the association between the predictor 
and criterion varies significantly at different levels of the moderator (Baron & Kenny, 1986). 
Post-hoc probing based on Holmbeck’s (2002) guidelines was conducted if mediation or 
moderation was found to be significant. Post-hoc probing of a mediational effect involves the 
hand-calculation of a z-test (i.e., bindirect effect/seindirect effect). Post-hoc probing of a moderational 
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effect consists of computation and plotting of the simple regression slopes. See Holmbeck (2002) 
for detailed procedures of post-hoc probing of significant mediational or moderational effects. 
Unless otherwise stated, all statistical analyses were performed with SPSS for Windows, 
Version 8.5. 
2.4.2 Missing or Incomplete Data 
Like most prospective RCTs, data were missing or incomplete for a subset of participants. Five 
participants experienced severe medication side effects within the first 14 days of the medication 
regimen. In each case, the medication randomization blind was broken for provision of medical 
care. All five participants were taking bupropion and were withdrawn due to following reasons: 
hypertension (N = 3), depression (N = 1), and edema (N = 1). Since their medication non-
completion was involuntary, these participants were excluded from all primary and secondary 
analyses.  
Self-report scales were classified as missing if greater than or equal to 25% of its items 
were missing. If scales were missing less than 25% of its items, missing questions were 
conservatively coded as neutral or asymptomatic (e.g., a missing BDI question was entered as 
zero). Thirty-one of the remaining 150 participants (20.7%) did not complete or were not 
administered one or more of the primary predictors of adherence. Nearly all missing data were 
due to failure of participants to complete one or more self-report measure. The proportions of 
participants with missing data for the primary predictors of adherence were as follows: (1) BDI = 
0.7%, (2) ISEL = 3.3%, (3) NEO/agreeableness and conscientiousness = 3.3%, (4) medication 
efficacy and outcome expectancies = 6% (of which 2% was due to experimenter error), (5) Week 
2 side effects = 1.3%, (6) Week 3 side effects = 6%, and (7) Week 5 side effects = 15.3%. 
Additionally, missing data existed for two potential covariates, including: (1) education status = 
2.7%, and (2) Fagerstrom Tolerance = 3.3%. Four participants were missing all of the following 
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data: ISEL, NEO/agreeableness and conscientiousness, medication efficacy and outcome 
expectancies, education status, and Fagerstrom tolerance.  
Finally, one participant with complete self-report data was withdrawn from the 
medication regimen after 16 days due to an adverse medication reaction to bupropion. Since the 
listwise mean number of prescribed days for the sample was 88 (SD = 8.3) and the second fewest 
number of prescribed days was 61, this participant was considered an outlier and excluded from 
subsequent analyses. 
To minimize the possibility of nonrandom missing data, the pattern of missingness was 
analyzed carefully using a series logistic regression analyses. The level of missingness of the 
psychosocial predictors of medication adherence and two possible covariates (education level 
and nicotine dependence) were re-coded as dummy variables (0 = non-missing, 1 = missing) and 
entered in separate hierarchical logistic regressions as dependent variables. Sociodemographic 
variables (age, race, education level, and body mass index), medication group, and counseling 
group, and nicotine dependence6 were entered as predictors in each of these models. Results 
from each of these logistic regression analyses were non-significant, indicating that missingness 
among the predictors was unrelated to several important characteristics. Given the relatively 
small proportions of missingness per individual variables and the fact that the predictors and 
possible covariates were apparently missing at random, listwise deletion was used in the primary 
analyses below.  
                                                 
6 Education level and nicotine dependence were not simultaneously entered as predictors and criterion variables. 
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3 RESULTS 
 
3.1 PRIMARY ANALYSES 
Initial data screening was conducted on all psychosocial variables. Descriptive statistics are 
presented in Table 2. All means and standard deviations were within valid ranges and were 
comparable to another sample of weight-concerned female smokers participating in a smoking 
cessation trial (e.g., Perkins et al., 2001) and to other non-clinical samples (Costa and McCrae, 
1992; Cohen et al., 1985). Although pretreatment side effects levels between the bupropion (M = 
8.89) and placebo (M = 4.90) groups were inexplicably different, F(1,116) = 5.51, p = .02, mean 
side effect levels at Week 5 were not significantly different between groups, F(1,116) = .732, p = 
.394, bupropion M =  13.63, placebo M = 11.56. Pretreatment and Week 5 side effects levels 
were collapsed across medication groups and are presented in Table 3. The pretreatment rates are 
comparable to ambient physical symptom levels of non-medical patients (Khosla, Bajaj, Sharma, 
& Mishra, 1992; Reidenberg & Lowenthal, 1968) and the Week 5 side effects levels are not 
substantively divergent from those reported by other individuals taking bupropion in clinical 
trials (Hurt et al., 1997; Jorenby et al., 1999; Hays et al., 2001). Given that there are no previous 
investigations of smoking cessation pharmacotherapy efficacy and outcome expectancies, a 
meaningful comparison with other samples was not possible. 
 
 
 53
Table 2 
 
Psychosocial Variables at Baseline 
 
             
 
Variable      Mean  Standard Deviation 
 
             
 
Beck Depression Inventory    6.26  5.85 
 
Interpersonal Support Evaluation List  94.18  14.93 
 
Medication efficacy expectancies   66.61  7.98 
 
Medication outcome expectancies   58.64  11.59 
 
NEO—Conscientiousness    33.88  5.67 
 
NEO—Agreeableness     33.51  5.25 
 
NEO—Extraversion     29.05  6.57 
 
NEO—Openness to Experience   27.06  6.01 
 
NEO—Neuroticism     18.69  6.23 
             
Note.  N = 118. 
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Table 3 
 
Self-Reported Medication Side Effects 
 
             
Side Effect      Percent Reporting 
     Pretreatment    Week 5  
             
 
Headache    27     12 
 
Blurred vision    3     2 
 
Anxious/nervous   20     28 
 
Tremor/shakiness   0     6 
 
Muscle spasms/muscle tension 13     7 
 
Drowsy    9     18 
 
Agitated/restless   13     27 
 
Dizzy     4     4 
 
Inability to sleep/insomnia  11     32 
          
Excessive sleep   5     5 
 
Increased saliva flow   2     3 
 
Poor concentration   4     15 
 
Disturbed concentration  7     13 
 
Irritability/anger/hostility  17     30 
 
Sweating    4     6 
 
Feeling too happy (feeling high) 1     7 
 
Hot flashes    14     9 
 
Short of breath   10     5 
 
Rapid or fluttering heart  3     2 
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Chest pain    2     2 
 
Strange taste in mouth  2     13 
 
Excessive thirst   3     13 
 
Dry mouth    2     21 
 
Poor appetite    3     6 
 
Increased appetite   7     20 
 
Heartburn    6     6 
 
Stomach pain    3     8 
 
Nausea/vomiting   1     6 
 
Excessive gas    4     11 
 
Inc. urinary frequency   1     12 
 
Dec. urinary frequency  1     3 
 
Inc. sex drive    1     1 
 
Dec. sex drive    0     4 
 
Itchy skin    6     6 
 
Skin rash or hives   3     2 
 
Muscle pain    13     5 
 
Joint pain    6     2 
 
Fever/chills    0     1   
             
Note. Pretreatment indicates prior to initiating the study medication. N = 112. 
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3.1.1 Description of Medication Adherence 
A relatively small proportion (6/118, or 5.1%) of participants were medication non-completers 
(i.e., less than 14 days with correct intake). The sample size of medication completers was 112. 
Given the relatively small size of this non-completer group and possible substantive differences 
between medication non-completers and completers, descriptive statistics are provided here for 
medication completers only (tests for differences between completers and non-completers are 
presented in the Prediction of Medication Adherence section below). As a check of MEMS 
methodology, participants were asked two self-report questions at medication check-ups/refills: 
(1) “Have you been using the MEMS bottle to dispense you medication? (yes/no)” and (2) “To 
what extent have you been using the MEMS cap to keep track of your pills? (1 = not at all, 7 = 
completely).” At Week 5, a large proportion (93/112) responded “yes” to the first question, and 
the mean response was 4.80 (SD = 2.18) to the second question. Thus, a majority of participants 
reported using the electronic cap and accompanying pill bottle, whereas the MEMS’ digital 
display was used to a moderate degree. As the MEMS’ digital display was intended to facilitate 
medication adherence, it is not surprising that the correlation between self-reported use of the 
electronic cap to keep track of pill intake and 90-day medication adherence was significant, 
albeit of modest magnitude, r = .25, p = .01.  
 Descriptive statistics for the full 90-day period, the 1st 30-day period, the 2nd 30-day 
period, and the 3rd 30-day period are presented in Table 4. As predicted, medication adherence 
defined with a variety of summary measures was far less than optimal over the full 90-day 
period. Each medication index also decreased over each of the three consecutive 30-day periods. 
For example, the mean of the most stringently defined adherence measure, incorporating both the 
prescribed number of doses and timing between doses, was 26.2% over the 90-day period and 
32.2%, 25.4%, and 19.1%, respectively, over the corresponding three 30-day periods. Even the  
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Table 4 
 
Descriptive Statistics for Summary Measures of Medication Adherence  
 
____________________________________________________________________________________________________________ 
 
Time Period         Mean # of          Mean % of          Mean % of          Mean % of          Mean % of          Mean % of        Mean % of  
                             prescribed          prescribed           days with            days with            days with            days with           days with 
            days                   doses taken         correct intake      drug holidays      underdosing        overdosing        correct intake           
                                                                                                               & timing 
                           between doses  
                   
 
90-days      88.5         72.8   58.0      21.8         15.6                     4.6                   26.2 
                  (5.02)               (25.6)   (24.3)      (25.1)        (13.6)                  (3.0)                (17.7) 
 
 
1st 30-days          29.6                    95.4  78.8      3.6         10.3                     7.4                   32.2 
                 (2.1)                   (12.8)                   (15.8)     (8.4)          (12.4)                  (4.2)                (17.3) 
 
 
2nd 30-days          29.7                    73.2   55.6     20.3         19.1                     5.0                   25.4 
                 (1.5)                    (32.3)            (29.9)               (29.9)        (17.8)                  (5.5)                (21.1) 
 
 
3rd 30-days          29.2                    50.7  39.5     41.6         17.5            1.4                   19.1  
                 (3.8)                   (41.4)            (37.5)     (44.8)        (22.7)            (3.2)                (24.1) 
                   
 
Note. N = 112. Standard deviations in parentheses. 
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least stringent adherence measure, indexing the percentage of prescribed doses taken, yielded a 
less than perfect rate of 72.8%. As expected, medication adherence progressively decreased over 
the 90-day period when operationalized with increasingly stringent criteria: % of prescribed 
doses taken: 72.8% > % of days with correct intake: 58.0% > % of days with correct intake and 
timing between doses: 26.2%.  
A correlation matrix among the summary measures of medication adherence is displayed 
in Table 5. The multicollinearity among these measures was quite variable, with a low 
correlation of ⎟ r⎟ = .03, p = .74, and a high correlation of ⎟ r⎟ = .95, p = .000. Despite near 
perfect multicollinearity among a few of these indices, most correlations were moderate to 
moderately strong in magnitude, suggesting that the use of multiple indices of medication 
adherence provided partially overlapping but not redundant information.  
Given the previously documented difficulties with the normality assumption for EEM-
measured adherence measures (Dunbar-Jacob et al., 1998b), the univariate normality of 90-day 
medication adherence was assessed by examining its distribution graphically (see histogram in 
Figure 1) and by performing formal inference tests of skewness and kurtosis.7 Although not 
perfectly bell-shaped, the distribution approximated normality and the z tests for skewness and 
kurtosis did not exceed the conventional but conservative .01 alpha level (Tabachnick & Fidell, 
1996). Consequently, the normality assumption was presumably supported, transformation was 
considered unnecessary, and linear regression modeling was used in subsequent analyses of 
medication adherence (i.e., percentage of days with correct intake).  
 
                                                 
7 Skewness: z = Skewness – zero / standard error of skewness; kurtosis: Kurtosis: z = Kurtosis – zero / standard 
error of kurtosis (Tabachnick & Fidell, 1996). 
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Table 5 
 
Correlations among Summary Measures of 90-Day Medication Adherence  
 
 
     1  2  3  4  5  6   
 
1.  % of prescribed    1.0  ---  ---  ---  ---  ---  
    doses taken  
 
2.  % of day with   .94*  1.0  ---  ---  ---  --- 
     correct intake    (.000)  
 
3.  % of days with   -.95*  -.84*  1.0  ---  ---  --- 
    drug holidays   (.000)  (.000)   
 
4.  % of days with   -.03  -.29*  -.26*  1.0  ---  --- 
     underdosing    (.737)  (.002)  (.007) 
 
5.  % of days with    .48*  .29*  -.37*  -.05  1.0  --- 
     overdosing    (.000)  (.002)  (.000)  (.602) 
 
6.  % of days with    .64*  .72*  -.55*  -.29*  .14  1.0 
     correct intake &   (.000)  (.000)  (.000)  (.002)  (.139) 
     timing between 
     doses 
____________________________________________________________________________________________________________ 
 
Note. N = 112. Two-tailed tests. Exact significance levels in parentheses below correlation coefficients 
* p < .01 
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Figure 1 
Histogram of the frequency distribution of the percentage of days with correct intake (with a 
superimposed normal curve). 
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3.1.2 Prediction of Medication Adherence 
A multiple regression logistic regression analysis was performed in order to characterize 
differences between medication completers and non-completers. Category of medication 
completion was entered as the criterion, and in order to maximize information about medication 
completion, several variables, including medication group, counseling group, age, race, 
education status, and Fagerstrom tolerance scores, were entered as predictors in the first step. 
First- and second-order psychosocial parameter terms were entered as predictors in the second 
and third steps, respectively. The final model is summarized in Table 6. The overall model was 
significant, χ2 (2) = 17.32, p = .000, R2L = .37, Hosmer-Lemeshow goodness-of-fit, χ2 (8) = 6.21, 
p = .624 (i.e., a well-fit model produces a non-significant χ2). Two variables were included in the 
final model: (1) race, unstandardized ß = -2.97, p = .006, odds ratio (OR) = .051, 95% 
confidence interval (CI) = .006-.434, and (2) conscientiousness, unstandardized β = .322, p = 
.005, OR = 1.38, 95% CI = 1.102-1.728. Likelihood ratio tests indicated that the removal of race 
or conscientiousness from the model resulted in significant decrements in model fit, ∆ in –2 log 
likelihood (1) = 7.33, p = .007, and ∆ in –2 log likelihood (1) = 16.74, p = .000, respectively. 
Thus, this fitted model indicates that individuals who are non-Caucasian or less 
conscientiousness were more likely to not complete the minimum threshold of medication 
adherence. Although the proportion of non-Caucasian participants was small (13/118, or 11.0%), 
the proportion of non-completers who were non-Caucasian was relatively large (3/6, or 50%). 
Given these differences, all subsequent analyses were conducted with medication completers (N 
= 112).  
Prior to performing linear regression analyses to predict medication adherence among 
completers, power analysis estimation for the linear regression model was computed using 
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Table 6 
 
Results of Regression Model on Medication Completion 
                   
 
Variable     β  Odds Ratio  95% CI  p-value 
____________________________________________________________________________________________________________
               
In model 
 Race/ethnicity    -2.97  .051   .006-.434  .006 
 Conscientiousness   .322  1.38   1.102-1.728  .005 
 
Failing to enter model (p > .10) 
 Medication group, Counseling group, Age, Education status, Fagerstrom tolerance scores 
 
 BDI, Agreeableness, ISEL, Medication efficacy expectancies, Medication outcome expectancies,  
 Week 2 (baseline) side effects, Week 3 side effects, Week 5 side effects 
 
 BDI-by-Week 5 side effects 
 Week 2-by-Week 3-by-Week 5 side effects 
                   
Note.  Overall Model A:  χ2 (2) = 17.32, p = .000.  N = 112. β is the unstandardized regression coefficient for the final regression 
model. Medication Completion: 0 = non-completion, 1 = completion; race/ethnicity: 1 = White, 2 = Black or Native Hawaiian/Pacific 
Islander. 
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Power Analysis and Sample Size Software 2000 (PASS, Kaysville, Utah). A two-sided .05 alpha 
level and a sample size of 112 participants were assumed. When predicting medication 
adherence, an R2 of .12 attributed to nine independent variables achieves 81% power, even after 
adjusting for an additional three covariates with an R2 of .10. Given that a recent meta-analysis 
of 12 studies assessing the association between depression and adherence to a variety of disease 
regimens reported that the pooled difference in risk of nonadherence between depressed and 
nondepressed patients was 27% (i.e., nondepressed patients manifesting better adherence; 
DiMatteo et al., 2000), power with the current sample size was deemed adequate.  
A multiple linear regression model was fit to determine whether any of the potentially 
confounding variables should be included in the final model. Specifically, medication group, 
counseling group, age, race, education status, and Fagerstrom tolerance scores were entered as 
predictors and 90-day medication adherence was set as the criterion. The overall model was 
significant, F(6, 105) = 2.27, p = .042, but age was the only significant predictor of medication 
adherence, t(111) = 2.10, p = .038, β = .21. In the subsequent hierarchical regression model of 
medication adherence, age was force entered in the first block of predictors and the first- and 
second-order psychosocial parameters were entered in the second and third blocks, respectively. 
The final model is summarized in Table 7. Although the overall model was significant, F(2,109) 
= 7.23, p = .001, age was not significantly associated with medication adherence, R2 ∆ = .028, 
t(111) = 1.47, p = .14. As predicted, conscientiousness scores accounted for a significant 
increment in the variance in medication adherence, R2 ∆ = .089, t(111) = 3.32, p = .001, β = .30. 
This effect indicates that higher levels of conscientiousness were associated with more favorable 
adherence, relative to lower levels of conscientiousness. Terms reflecting all other predictor 
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Table 7  
 
Results of Regressing Primary Psychosocial Variables on 90-Day Medication Adherence 
                   
 
Variable     β   R2 ∆   Significance of change 
                   
 
In model 
 Conscientiousness   .30   .089   t(111) = 3.32, p = .001 
  
 Overall model       .117   F(2,109) = 7.23, p = .001 
 
Failing to enter model (p > .10)      
 Age      
 
BDI, Agreeableness, ISEL, Medication efficacy expectancies, Medication outcome expectancies 
Week 2 (baseline) side effects, Week 3 side effects, Week 5 side effects 
 
BDI-by-Week 5 side effects, Week 2-by-Week 3-by-Week 5 side effects 
                   
Note.  N = 112. β is the standardized regression coefficient for the final regression model. 
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variables and interactions failed to approach significance (i.e., p > .10) and were eliminated from 
the final regression model. 
3.1.3 Prediction of Smoking Abstinence 
Prior to performing analyses to predict smoking cessation, a power analysis was conducted using 
an effect size from previous research on adherence and smoking cessation (Killen et al., 1997). A 
logistic regression of a binary response variable (smoking abstinence) on a continuous predictor 
with a sample size of 112 achieves 83% power to detect a 15% change in probability of smoking 
abstinence between mean medication adherence and one standard deviation above the mean. 
Killen et al. (1997) reported a 30% difference in smoking relapse at 3-month follow-up between 
those who adhered to the nicotine patch treatment instructions (40% relapsed) compared to those 
who did not adhere (70% relapsed). Thus, power to detect a moderate effect of adherence on 
smoking cessation with the present study was deemed adequate.  
Four logistic regression analyses were performed to examine the effects of 90-day 
medication adherence and the only significant psychosocial predictor of adherence, 
conscientiousness, on smoking cessation. In these smoking cessation analyses, prolonged 
smoking abstinence entered as the dichotomous criterion variable. Again, an initial logistic 
regression model was fit to determine whether any of the potentially confounding variables 
should be included in the final model. A final solution for the overall model could not be fit as 
none of the predictors (including medication and counseling treatments) significantly predicted 
prolonged abstinence (p > .065). As a result, no covariates were entered into subsequent models.  
A second logistic regression model was analyzed with the main effect of medication 
adherence entered as the only predictor variable. As seen in Table 8A, results indicated that the 
model was a good fit, χ2 (1) = 13.18, p = .000, R2L = .087, Hosmer-Lemeshow goodness-of-fit,  
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Table 8 
 
Results of Two Logistic Regression Models on Prolonged Smoking Abstinence 
                   
 
 Predictor    β  Odds Ratio  95% CI  p-value    
                   
 
A. 90-day medication adherence  .031  1.031   1.013-1.049  .000 
               
                   
 
B. Conscientiousness   .035  1.036   .967-1.110  .320 
                   
Note.  Overall Model A:  χ2 (1) = 13.18, p = .000; Overall Model B:  χ2 (1) = 1.00, p = .317. N = 112. β is the unstandardized 
regression coefficient for the final regression model. 
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χ2 (8) = 7.04, p = .532, and that medication adherence was significantly associated with 
increased likelihood of prolonged smoking abstinence, unstandardized β = .031, p = .000, OR = 
1.031, 95% CI = 1.013-1.049. The likelihood ratio test indicated that the removal of medication 
adherence from the model resulted in significant decrement in model fit, ∆ in –2 Log Likelihood 
(1) = 13.24, p = .000.  
A third logistic regression model was analyzed with the main effect of conscientiousness 
entered as the predictor variable. The model was not significant, χ2 (1) = 1.00, p = .317, 
indicating that inclusion of conscientiousness did not improve the prediction of prolonged 
smoking abstinence (see Table 8B). This null finding suggests that conscientiousness did not 
mediate the relationship between medication adherence and smoking abstinence in this study. 
Finally, to assess for a possible moderational effect on smoking cessation, a multiple 
logistic regression model was analyzed with the main effects of medication adherence and 
conscientiousness entered as predictor variables in the first step and the interaction between 
medication adherence and conscientiousness entered in the second step. In order to remove 
potentially high levels of non-essential multicollinearity between the main effects and the 
interaction term (Aiken & West, 1991), 90-day medication adherence and conscientiousness 
were centered about their respective means before testing the significance of the interaction term. 
The overall model was a significant fit, χ2 (3) = 13.65, p = .003, R2L = .090, Hosmer-Lemeshow 
goodness-of-fit, χ2 (8) = 6.91, p = .55, but the interaction term was not a significant predictor of 
smoking abstinence, χ2 (1) = 0.449, p = .503. Medication adherence again accounted for a 
significant proportion of the variance in prolonged smoking abstinence, unstandardized β = .031, 
OR = 1.031, 95% CI = 1.013-1.051. Thus, these results suggest that conscientiousness and 
medication adherence did not form a moderating relationship. 
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 3.2 SECONDARY ANALYSES 
3.2.1 Prediction of Medication Adherence with Alternative Psychosocial Factors 
Although conscientiousness and agreeableness were the only personality factors tested in 
primary analyses, the effects of all Big Five dimensions were assessed concurrently in secondary 
analyses. A multiple stepwise linear regression model was computed with 90-day medication 
adherence entered as the dependent variable and the five personality factors entered as the 
predictor variables. The overall model fit the data well, R2 = .187, F(3, 108) = 8.27, p = .000, and 
is summarized in Table 9. Age was again force entered in the first step and in this instance was 
significantly associated with medication adherence, R2 ∆ = .028, t(108) = 2.12, p = .037, β = 
.189. As in the primary analyses, conscientiousness was positively associated with medication 
adherence, R2 ∆ = .089, t(108) = 3.68, p = .000, β = .32. Openness to experience also accounted 
for a significant increment in the variance in medication adherence, R2 ∆ = .070, t(108) = 3.04, p 
= .003, β = .27. This result indicates that higher levels of openness to experience were associated 
with more favorable adherence, relative to lower levels of openness. Terms reflecting all other 
Big Five factors failed to approach significance (i.e., p > .40) and were eliminated from the final 
regression model.  
With the exception of side effects, all primary analyses were conducted with predictors 
measured prior to initiating medication or counseling treatments and attempting to quit smoking. 
Although not hypothesized, it is possible that individual differences in psychosocial variables 
measured a few weeks after beginning treatment and quitting smoking influenced medication 
adherence and/or prolonged smoking abstinence distinctly from the same variables measured  
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Table 9 
 
Results of Regressing All Dimensions of the Five-Factor Model of Personality on 90-Day Medication Adherence 
                   
 
Variable     β   R2 ∆   Significance of change    
                   
                   
 
In model 
 
 Age     .19   .028   t(108) = 2.12, p = .037 
  
 Conscientiousness   .32   .089   t(108) = 3.68, p = .000 
 
 Openness to Experience  .27   .070   t(108) = 3.04, p = .003 
 
Failing to enter model (p > .40) 
 
 Agreeableness, Extraversion, Neuroticism 
                   
Note.  N = 112. Overall model, F(3, 108) = 8.27, p = .000. β is the standardized regression coefficient for the final regression model. 
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before treatment. For this reason, the effects of Week 6 BDI, Week 6 medication outcome 
expectations, and Week 6 ISEL were analyzed in secondary analyses. Given the prospective 
nature of this assessment, it is not surprising that missing data existed among the sample of 112 
medication completers. The proportions of participants with missing data were as follows: Week 
6 BDI = 11.6%, Week 6 medication outcome expectancies = 11.6%, and Week 6 ISEL = 18.8%. 
To maintain an N of 112, missing data were imputed with the means of the non-missing cases. 
Then, a stepwise linear regression model was computed with 90-day medication adherence 
entered as the criterion variable, age entered in the first predictor step, and the three Week 6 
psychosocial parameters entered in the second predictor step.8 The final model is summarized in 
Table 10. The overall model was significant, R2 = .107, F(2, 109) = 6.50, p = .002. Age did not 
account for a significant amount of variance in medication adherence, R2 ∆ = .028, t(109) = 1.86, 
p = .065, but Week 6 ISEL scores were positively associated with increased medication 
adherence, R2 ∆ = .079, t(109) = 3.10, p = .002, β = .28. For heuristic purposes, the correlation 
between Week 6 ISEL and Week 6 BDI scores was computed. Since it was moderately strong, r 
= -.45, p = .000, a univariate model with Week 6 BDI as the sole predictor was computed. 
Interestingly, Week 6 BDI scores would have been significantly and negatively associated with 
medication adherence had Week 6 ISEL scores not been entered concurrently, R2 ∆ = .084, 
t(109) = -2.59, p = .011, β = -.24. These results suggest that social support accounts for 
variability in medication adherence over and above depressive symptoms but not vice versa.  
                                                 
8 This analysis was also conducted using participants with complete data only and the results were comparable, i.e., 
the overall model was significant, R2 = .123, F(2, 78) = 5.48, p = .006; age did not account for a significant amount 
of variance in medication adherence, R2 ∆ = .021, t(78) = 1.59, p = .115; Week 6 ISEL scores were positively 
associated with increased medication adherence, R2 ∆ = .102, t(78) = 3.01, p = .004, β = .32. 
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Table 10 
 
Results of Regressing Week 6 Psychosocial Variables on 90-Day Medication Adherence 
                   
 
Variable     β   R2 ∆   Significance of change 
                   
 
In model 
 Week 6 ISEL    .28   .079   t(109) = 3.10, p = .002 
 
Failing to enter model (p > .10) 
 Age, Week 6 BDI, Week 6 medication outcome expectancies 
                   
Note.  N = 112. Missing data for Week 6 ISEL, BDI, and medication outcome expectancies were imputed with means of respective 
non-missing cases. Overall model, F(2, 109) = 6.50, p = .002. β is the standardized regression coefficient for the final regression 
model. 
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3.2.2 Prediction of Smoking Abstinence with Alternative Psychosocial Factors  
In order to test for mediational or moderational effects related to smoking abstinence, a series of 
logistic regression models were computed with alternative psychosocial variables found to be 
associated with medication adherence entered as predictors. First, a logistic regression model 
was analyzed with the main effect of openness to experience entered as the predictor variable 
and prolonged smoking abstinence entered as the criterion variable. Results indicated that the 
model was a good fit, χ2 (1) = 4.50, p = .034, R2L = .0295, and Hosmer-Lemeshow goodness-of-
fit, χ2 (8) = 6.08, p = .638, and that openness to experience was significantly associated with 
increased likelihood of prolonged smoking abstinence, unstandardized β = .069, p = .039, OR = 
1.072, 95% CI = 1.003-1.145. To test whether medication adherence mediated the association 
between openness to experience and smoking abstinence, the effect of medication adherence on 
prolonged smoking abstinence was assessed, controlling for openness to experience. A logistic 
regression model was fit, χ2 (2) = 15.41, p = .000, R2L = .1011, Hosmer-Lemeshow goodness-of-
fit, χ2 (8) = 7.92, p = .442, showing that medication adherence predicted increased smoking 
abstinence, unstandardized β = .028, p = .002, OR = 1.029, 95% CI = 1.011-1.047, after 
controlling for openness to experience. Since the three pre-conditions of mediation were 
achieved (Baron & Kinney, 1986), post-hoc probing of the indirect effect was conducted. The 
statistical test for mediation (Holmbeck, 2002) demonstrated that the indirect effect was 
significant, z = 2.00, p = .023, indicating that the drop in the total effect (i.e., the path between 
openness to experience and smoking abstinence) was statistically significant upon inclusion of 
medication adherence in the model. Thus, medication adherence was a significant mediator of 
the openness to experience/smoking abstinence relationship, accounting for 39.7% of the 
variance. 
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Next, a logistic regression model was computed with Week 6 ISEL entered as the 
predictor variable and smoking abstinence as the criterion. The model fit adequately, χ2 (1) = 
5.88, p = .015, R2L = .0386, Hosmer-Lemeshow goodness-of-fit, χ2 (7) = 7.77, p = .354, and 
results indicated that social support was significantly associated with increased likelihood of 
prolonged smoking abstinence, unstandardized β = .036, OR = 1.037, 95% CI = 1.006–1.069. 
When controlling for Week 6 ISEL, a model with 90-day medication adherence predicting 
prolonged smoking abstinence was a significant fit, χ2 (1) = 15.623, p = .000, R2L = .1025, 
Hosmer-Lemeshow goodness-of-fit, χ2 (7) = 9.007, p = .342, unstandardized β = .027, p = .003, 
OR = 1.028, 95% CI = 1.010-1.046. The statistical test for mediation showed that the indirect 
effect was significant, z = 2.14, p = .016, indicating that medication adherence was a significant 
mediator of the Week 6 ISEL/smoking abstinence relationship (accounting for 37.2% of the 
variance). As previously mentioned, Week 6 BDI scores were significantly associated with 
prolonged smoking abstinence when entered as the sole predictor (i.e., without Week 6 ISEL). 
For heuristic purposes, a mediational test involving BDI/medication adherence/prolonged 
smoking abstinence was explored. The test was significant, z = -1.81, p = .035, indicating that 
medication adherence significantly mediated the association between depressive symptoms and 
prolonged smoking abstinence (accounting for 22.48% of variance), but only when ISEL scores 
were precluded.  
Finally, an exploratory hierarchical logistic regression analysis was conducted to determine 
whether any of the psychosocial parameters unrelated to medication adherence were associated 
with prolonged smoking abstinence. Specifically, the following main effect terms were entered 
in the first step of the model: agreeableness, neuroticism, extraversion, baseline BDI, baseline 
ISEL, baseline and Week 6 medication outcome expectations, baseline self-efficacy 
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expectations, and Weeks 2, 3, and 5 side effects. The overall model was significant, χ2 (2) = 
15.45, p = .000, R2L = .1014, Hosmer-Lemeshow goodness-of-fit, χ2 (8) = 6.75, p = .564, and is 
summarized in Table 11. Two variables were included in the final model: (1) agreeableness, 
unstandardized ß = .096, p = .018, OR = 1.101, 95% CI = 1.016-1.192, and (2) Week 6 
medication outcome expectations, unstandardized ß = .048, p = .005, OR = 1.049, 95% CI = 
1.015-1.085. Likelihood ratio tests indicated that the removal of Agreeableness or Week 6 
medication outcome expectations from the model resulted in significant decrements in model fit, 
∆ in –2 Log Likelihood (1) = 6.04, p = .014, and ∆ in –2 Log Likelihood (1) = 9.42, p = .002, 
respectively. Thus, individuals with higher agreeableness scores and Week 6 medication 
outcome expectations tended to maintain smoking abstinence more successfully than individuals 
scoring low on either of these variables.  
In order to better characterize the openness to experience/smoking cessation relationship, 
another possible mediator was examined, that is, Week 6 medication outcome expectancies. The 
zero-order correlation between openness to experience and Week 6 medication outcome 
expectations was in fact significant, r = .24, p = .012, so a test for statistical mediation was 
conducted. The indirect effect was significant, z = 1.76, p = .039, indicating that Week 6 
medication outcome expectations significantly mediated the openness to experience/smoking 
abstinence relationship (accounting for 32.8% of the variance). 
Finally, the possibility that Week 6 ISEL mediated the agreeableness/prolonged smoking 
abstinence association was explored. Although two pre-conditions of mediation were achieved, 
(1) agreeableness was significantly associated with Week 6 ISEL, r = .28, p = .003, and (2) 
agreeableness was significantly associated with prolonged smoking abstinence (see above), 
Week 6 ISEL scores did not predict prolonged smoking abstinence when adjusting for  
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Table 11 
 
Results of Regressing Psychosocial Variables Unrelated with Medication Adherence on Prolonged Smoking Abstinence 
                   
 
Variable     β  Odds Ratio  95% CI  p-value 
                   
 
In model 
 Agreeableness    .096  1.101   1.016-1.192  .018   
 
 Week 6 medication outcome   .048  1.049   1.015-1.085  .005 
  expectancies 
 
Failing to enter model (p > .10) 
 Neuroticism, Extraversion, Baseline BDI, Baseline ISEL, Baseline medication outcome expectations 
 Baseline self-efficacy expectations, Weeks 2 side effects, Week 3 side effects, Week 5 side effects 
                   
Note.  Overall Model χ2 (2) = 15.45, p = .000.  N = 112. Missing data for Week 6 medication outcome expectancies were imputed 
with means of non-missing cases. β is the unstandardized regression coefficient for the final regression model. 
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agreeableness, ß = .029, p = .069. Thus, this later null finding suggested that Week 6 ISEL was 
not a significant mediator. 
3.2.3 Main Effect of Medication Adherence on Smoking Abstinence: Possible Influences 
The aim of the next set of logistic regression analyses was to shed light on possible explanations 
for the main effect of medication adherence on prolonged smoking abstinence. If the main effect 
of 90-day medication adherence lost its statistical significant when adjusting for potentially 
important psychosocial variables, this would suggest a plausible, but not causal, psychosocial 
mechanism underlying the influence of adherence. As described above, the main effect of 
medication adherence on prolonged smoking abstinence was not attenuated when entering 
conscientiousness prior to medication adherence. Two more multiple logistic regression model 
were fit with psychosocial parameters related to medication adherence (openness to experience 
and Week 6 ISEL) entered prior to medication adherence as predictors and prolonged smoking 
abstinence entered as the criterion. When adjusting for openness to experience, the overall model 
was statistically significant, χ2 (2) = 15.41, p = .000, but the main effect of medication adherence 
on smoking cessation was not attenuated, unstandardized ß = .028, p = .002, OR = 1.029, 95% 
CI = 1.011-1.047. Similarly, when adjusting for Week 6 ISEL, the overall model was statistically 
significant, χ2 (2) = 15.62, p = .000, but the main effect of medication adherence on smoking 
cessation remained significant, unstandardized ß = .027, p = .003, OR = 1.028, 95% CI = 1.010-
1.046. 
A final stepwise multiple logistic regression model was fit with all remaining first-order 
psychosocial terms entered prior to 90-day medication adherence. Again, the overall model was 
a good fit, χ2 (2) = 25.14, p = .000, and the main effect of medication adherence was still 
significant, unstandardized ß = .028, p = .003, OR = 1.028, 95% CI = 1.010-1.047. In sum, these 
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results did not implicate any measured psychosocial mechanisms that may underlie the main 
effect of adherence on smoking cessation.  
3.2.4 Prediction of Smoking Abstinence with all Six Summary  
In the primary analyses, medication adherence was operationalized with the “percentage of 
prescribed administrations taken” summary index. In order to compare the relative predictive 
utility of the numerous summary measures of medication adherence that were computed, a 
stepwise multiple logistic regression analysis was conducted with all six summary measures of 
90-day medication adherence entered as predictors and prolonged smoking abstinence entered as 
the criterion. The final model is summarized in Table 12. The overall model was significant, χ2 
(1) = 17.84, p = .000, R2L = .12, Hosmer-Lemeshow goodness-of-fit, χ2 (7) = 3.82, p = .800. 
Interestingly, the measure indexing percentage days with drug holidays was significantly 
associated with decreased likelihood of maintaining prolonged smoking abstinence, 
unstandardized ß = -.037, p = .000, OR = .963, 95% CI = .945-.982. The likelihood ratio test 
showed the dropping the drug holiday index from the model resulted in significant decrement in 
model fit, ∆ in –2 Log Likelihood (1) = 18.27, p = .000. None of the other five summary 
measures of adherence remained in the final model (p > .10), suggesting that failure to take 
medication for one or more consecutive days was the most robust predictor of failing to maintain 
prolonged smoking abstinence.  
3.2.5 Temporal Nature of the Medication Adherence-Smoking Abstinence Relationship 
In primary analyses, logistic regression modeling showed that 90-day medication adherence (i.e. 
percentage of days with correct intake) was positively related to prolonged smoking abstinence. 
However, those results were not capable of differentiating direction of causality, that is, 
medication adherence may have led to enhanced smoking abstinence, smoking abstinence may 
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have led to enhanced medication adherence, or both may have been antecedents of one another. 
A cross-lagged panel design was used to test hypotheses regarding the temporal nature of the 
relationship between medication adherence and smoking abstinence. It is important to note that 
the plausibility of a causal relationship is strengthened, but by no means proved, by utilizing this 
quasi-experimental design in which variables are collected at least twice over time (Kenny, 
1975).  
Since medication adherence and prolonged smoking abstinence were global measures of 
the entire study period, they do not provide information about fluctuations of these behaviors 
over time. Therefore, the three 30-day measures of medication adherence and point-prevalence 
smoking abstinence measures taken during each of these 30-day periods were designated as the 
components of the cross-lagged panel design.9 For simplicity, the 1st, 2nd, and 3rd 30-day 
medication adherence periods are referred to as A1, A2, and A3, respectively, and point-
prevalence smoking abstinence at day 28, 56, and 84 are referred to as P1, P2, and P3, 
respectively, in this cross-lagged panel design. The design is outlined in Figure 2. Tentative 
conclusions about the direction of medication adherence—smoking abstinence associations can 
be established by comparing the correlation coefficients representing A1-P2 versus P1-A2, as 
well as the cross-lagged correlations of A1-P3 versus P1-A3 and A2-P3 versus P2-A3. Assuming 
that presumed causal variables precede presumed effect variables in time (Leary, 1995), 
hypotheses regarding medication adherence causing increased smoking abstinence are supported  
                                                 
9 It is important to note that point-prevalence abstinence is measured independently over 
repeated occasions. Although having one cigarette is a strong predictor of relapse over time, it is 
possible to be classified as having been non-abstinent at one point-prevalence abstinence time 
point but abstinent at a subsequent time point. 
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Figure 2  
 
A1 
 
A2
 
A3
 
P1 
 
P2
 
P3
.201c*
.715b***.704b***
.760a***.663a***
.423a***
 .586b***
.330c***
.288c**
.421c***
 .237c*
.187c*
.243c*
.081c 
Cross-Lagged panel design involving three 30-day medication adherence periods and corresponding point-prevalence smoking 
abstinence rates. 
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Note.  N = 112. Two-tailed tests. A1 = % of days with the correct number of doses during the first 30-day period, A2 = % of days with 
the correct number of doses during the second 30-day period, A3 = % of days with the correct number of doses during the third 30-day 
period, P1 = point-prevalence abstinence at Day 28 (0 = not abstinent, 1 = abstinent), P2 = point-prevalence abstinence at Day 56, P3 
= point-prevalence abstinence at Day 84. 
a Pearson-produce moment correlation. 
b Phi coefficients (rφ). 
c Point-biserial correlation. 
* p < .05 
** p < .01 
*** p < .001 
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if cross-lagged correlations A1-P2, A2-P3, and A1-P3 are significantly greater than correlations 
P1-A2, P2-A3, and P1-A3, respectively. 
 In order to support the viability of the cross-lagged panel design, the assumptions of 
synchronicity and stationarity (Kenny, 1975) were considered. The synchronicity assumption 
necessitates that the predictor and criterion variables are measured contemporaneously over a 
minimum of two distinct points in time for the same individuals. The stationarity assumption 
requires that the underlying structural relationship between the predictor and criterion variables 
do not vary between the two or more measurement time points. Violations of stationarity are 
assumed to have occurred if the synchronous correlations (i.e., correlations between the predictor 
and criterion variables at the same time point, such as A1-P1, A2-P2, and A3-P3) are 
significantly different over time.  
Autocorrelations (i.e., correlations of the same variable at two or more points in time), 
synchronous correlations, and cross-lagged correlations were calculated in order to evaluate the 
cross-lagged panel design. Since medication adherence was indexed continuously, Pearson-
product moment correlations were computed for the A1-A2, A2-A3, and A1-A3 
autocorrelations. Since point-prevalence smoking abstinence was indexed dichotomously, phi 
coefficients (rφ) were computed for the P1-P2, P2-P3, and P1-P3 autocorrelations. Point-biserial 
correlations (rpb) were computed for the A1-P2, A2-P3, A1-P3, P1-A2, P2-A3, and P1-A3 cross-
lagged correlations.10 Differences between correlations were tested with the Pearson-Filon z-test 
(as cited by Kenny, 1975). Since Pearson and point-biserial correlations are subject to the 
univariate normality assumption, medication adherence indices were transformed in order that 
                                                 
10 SPSS for Windows 8.5 calculates point-biserial correlations using the eta statistic. Hand-calculated point-biserial 
correlations were identical to the eta statistic. 
resulting skewness and kurtosis values were within conventional levels (Tabachnick & Fidell, 
1996). Specifically, the cube of A1 and the square of A2 and A3 were used in these cross-lagged 
panel design analyses. 
Assumptions were evaluated initially. Since A1-P1, A2-P2, and A3-P3 correlations were 
measured at roughly the same respective time periods over three consecutive intervals, the 
synchronicity assumption was supported. Inequality of the synchronous correlations A1-P1 (rpb = 
.065, p > .10) versus A2-P2 (rpb = .243, p < .02), z = -1.67, p = .048, and A1-P1 (rpb = .065) 
versus A3-P3 (rpb = .330, p < .001), z = -1.99, p = .023, suggested that the stationarity 
assumption was violated for the Time 1 panel. The synchronous correlations A2-P2 (rpb = .243) 
and A3-P3 (rpb = .330) were not significantly different, z = -1.16, p = .123, thereby validating the 
stationarity assumption for the Time 2 and 3 panels. Autocorrelations for medication adherence 
were moderate (A1-A3, r = .423, p = .000) to strong (A1-A2: r = .663, p = .000; A2-A3: r = .760, 
p = .000). Autocorrelations for point-prevalence abstinence were moderately strong (P1-P3: rφ = 
.586, p = .000) to very strong (P1-P2: rφ = .704, p = .000; P2-P3: rφ = .715, p = .000). The cross-
lagged correlation between A2 and P3 was moderate (rpb = .421) and significant (p < .001), 
whereas the corresponding cross-lagged correlation between P2 and A3 was smaller (rpb =  .237), 
although still significant (p < .02). The Pearson-Filon z-test revealed that these cross-lagged 
correlations were significantly different, z = 2.25, p = .01. To recapitulate, these results indicate 
that medication adherence during the second 30-day period was associated with subsequent 
increased risk of being abstinent from smoking during the final week of the study period. At the 
same time, these results also suggest that being abstinent from smoking during the mid-point of 
the study period increased the likelihood of maintaining adherence to the medication regimen 
during the final 30-day period. When comparing whether the temporal precedence of medication 
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adherence versus point-prevalence abstinence, results suggested that medication adherence was 
the stronger antecedent of the two. 
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4 DISCUSSION 
 
The purpose of this investigation was to examine the rates, predictors, and sequelae of adherence 
to a 90-day medication regimen among weight-concerned female smokers participating in a 
smoking cessation trial. Primary and secondary analyses yielded several significant results, 
including: 
1.  Ninety-day medication adherence operationalized with a variety of summary indices 
was suboptimal, with the rates varying from 26% (i.e., via a conservative measure of 
percentage of days with correct number of doses and timing between doses) to 73% (i.e., 
via a liberal measure of percentage of total doses taken over 90 days). Moreover, each 
index showed substantial decrements in medication adherence over each successive 30-
day period. 
2.  Increased levels of conscientiousness were significantly associated with successful 
completion of a minimum duration of the medication regimen. Caucasian participants 
were also more likely to complete the minimum medication regimen than non-Caucasian 
participants. Increased levels of conscientiousness, openness to experience, and Week 6 
social support were associated with more favorable 90-day medication adherence. 
3.  Medication adherence was significantly associated with successful smoking cessation, 
such that individuals manifesting more favorable adherence were more likely to maintain 
prolonged smoking abstinence. Increased levels of openness to experience, Week 6 social 
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support, Week 6 medication outcome expectancies, and agreeableness were also 
associated with an increased likelihood of maintaining smoking abstinence.  
4.  Post-hoc analyses revealed that medication adherence significantly mediated the 
associations between openness to experience and smoking abstinence, and between Week 
6 social support and smoking abstinence. Week 6 medication outcome expectancies also 
mediated the association between openness to experience and smoking abstinence.  
5.  Cross-lagged panel correlations between the three 30-day periods of medication 
adherence and three measures of point-prevalence smoking abstinence suggested that 
medication adherence and abstinence were significant antecedents on one another.    
Follow-up tests indicated that adherence was the stronger precursor of the two. 
6.  In a comparison of six summary measures of medication adherence, the index of drug 
holidays was the best predictor of smoking abstinence. 
4.1 Rates of Medication Adherence 
To my knowledge, this is the first full-length report of adherence rates in a double-blind, 
placebo-controlled trial using bupropion for the treatment of tobacco dependence. Six summary 
measures of medication adherence were computed, but only one index, the percentage of days 
with correct intake, was used in the primary inferential analyses due to two reasons: (1) its 
balanced operationalization of quantity and timing of dose administrations, and (2) the 
minimization of Type I error. Among individuals with complete baseline data and no 
medication-related adverse events, initial analyses indicated that only six participants failed to 
complete a minimum number of days with correct intake. For the sub-sample of medication 
completers, the mean percentage of days with the correct medication intake was 58% for the 90-
day period, 79% for the first 30-day period, 56% for the second 30-day period, and 40% for the 
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last 30-day period. As anticipated, the initial 30-day period was a relative “honeymoon” with the 
highest level of adherence for the sample, but these rates progressively fell throughout the 90-
day period. Descriptive statistics with the other five summary measures corroborated this pattern 
of findings, as well.  
Given the lack of empirical data on bupropion adherence, there are no established 
guidelines for defining a therapeutically adequate level of adherence. However, Insull (1997) 
reviewed studies of EEM-measured medication-taking behavior for seizure disorders, glaucoma, 
asthma, cardiology disorders, and hypertension and recommended three clinically-relevant 
categories of adherence: (1) adherent (> 80%), partially adherent (20%-79%), and non-adherent 
(< 20%). Insull (1997) also reported the typical distribution frequencies for these categories: 
adherent—50% to 60%, partially adherent—30% to 40%, and non- adherent—5% to 10%. As 
done by Sereika and Dunbar-Jacob (2001), applying these categorical thresholds to the present 
study’s adherence data resulted in the following frequency distribution: adherent—25%, partially 
adherent—70%, and non- adherent—5%. Thus, the percentage of individuals in the non-adherent 
category was similar to Insull’s (1997), but the distribution of the adherent and partially-adherent 
categories were reversed in the present study. It is somewhat surprising that medication 
adherence was relatively inferior in this smoking cessation trial, given the relatively short 
duration of the medication regimen and the substantial hurdles individuals overcame to 
participate in the project (e.g., the intensive screening process included a physical exam, a SCID, 
multiple questionnaires, etc.). One possible explanation for the differences in distribution 
frequencies is the immediacy of the health threats posed by cigarette smoking versus existing 
chronic medical conditions. That is, quitting smoking is a preventive health behavior with 
potentially long-term benefits, whereas adhering to a medication regimen designed to ameliorate 
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an existing chronic disorder may have more immediate payoffs, such as reducing the possibility 
of experiencing a seizure or myocardial infarction. Methodologically, an important benefit of a 
larger partially adherent group in the present study was a sample distribution approximating 
normality. This observed adherence distribution was inconsistent with the J-shaped distribution11 
commonly reported for adherence behaviors across a wide array of assessment methods and 
disease regimens (Dunbar-Jacob et al., 1998b). Whereas the adherence literature is largely 
characterized by dichotomizing adherence (e.g., > 80% = good adherence, < 80% = poor 
adherence), the present study’s distribution allowed for the operationalization of medication 
adherence data continuously, the use of parametric statistics, and the concomitant maximization 
of statistical power. 
It is noteworthy that medication adherence rates were measured in this study with MEMS 
Smart Caps, which provided real-time information on quantity and timing of dose 
administrations to participants in their daily lives. The importance of self-monitoring is 
underscored by previously reported findings that electronic monitors elicit participant reactivity 
and may actually enhance adherence behavior. For example, McKenney, Munroe, and Wright 
(1992) demonstrated that adherence was significantly elevated  (p = .002) in the group using an 
electronic pill monitor (80%) with those using the standard pill bottle and cap (78%). Moreover, 
informing participants of the importance of using an electronic pill cap for clinical or research 
purposes may encourage them to be more adherent. For example, Kruse and Weber (1990) 
reported that 91% of individuals informed about the electronic medication monitor were adherent 
                                                 
11 The J-shaped distribution usually consists of a majority of individuals being highly adherent (> 
90%), a smaller proportion ranging from 10% to 90% adherent, and a small increase in the less 
than 10% range (Dunbar-Jacob et al., 1998b).  
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whereas 78% of uninformed individuals were adherent. In the present study, all participants were 
informed about the research purpose of the MEMS caps and were encouraged to use the caps’ 
digital displays to facilitate adherence. Indeed, the correlation between the participants’ self-
reported usage of the MEMS cap to keep track of medication consumption and actual EEM-
measured adherence was statistically significant. Although the MEMS Smart Caps’ digital 
display may have enhanced overall rates of adherence, the relatively suboptimal 90-day 
adherence rate argues against the possibility that the present findings were substantively biased 
in a positive direction and therefore invalid. In fact, it is debatable whether the widespread 
availability of inexpensive pill organizers in commercial pharmacies makes the present study’s 
findings more externally valid than medication studies not using self-monitoring devices. In the 
end, the only way to reach definitive conclusions regarding the effects of dosing administration 
information on medication-taking behavior would be to randomize participants to use caps with 
or without digital displays in a true experimental design. 
4.2 Prediction of Medication Adherence 
One of the strengths of this study was the examination of several psychosocial variables that are 
commonly explored in a univariate manner, but in fact are empirically and conceptually 
interrelated. This multivariate approach allowed for the examination of the independent 
contributions of psychosocial parameters along with potentially overlapping or redundant 
constructs, in addition to permitting exploration of mediational and moderational effects. 
Importantly, preliminary analyses revealed that several potentially confounding variables, 
including levels of medication treatments (bupropion vs. placebo) and counseling treatments 
(CBT for weight concerns vs. standard behavior therapy), were unrelated with medication 
adherence. This evidence suggested that the interventions were not a confounding influence on 
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medication adherence, and as such, subsequent regression analyses were conducted by collapsing 
across levels of medication. It is also suggests that the effects of psychosocial variables on 
medication adherence were independent of any active treatments. 
Although not the focus of the present study, the failure to detect a main effect of 
medication status (bupropion versus placebo) on smoking cessation rates is an important 
deviation from previous findings (Hurt et al., 1997; Jorenby et al., 1999; Hays et al., 2001) and 
thus warrants some discussion. The most likely explanation for this null finding was the lack of 
statistical power. Regression analyses in the present study relied on 112 participants, whereas 
previous studies reporting positive findings utilized samples well over 600 participants (Hurt et 
al., 1997; Jorenby et al., 1999; Hays et al., 2001). Another major difference was the intensive 
nature of group counseling in the present study. That is, participants attended twelve ninety-
minute cognitive-behavioral group therapy sessions and five nurse visits over the course of the 
90 days of treatment. In contrast, Hurt et al. (1999) provided self-help materials, a physician-
based message, and brief (10-15 minutes) weekly individual counseling sessions over seven 
weeks, and similarly, Jorenby et al. (1999) provided brief (less than or equal to 15 minutes) 
weekly individual counseling sessions over nine weeks. It is possible that the relative 
thoroughness of counseling in the present study diluted potential differences between medication 
groups. Moreover, although differences in smoking cessation rates between bupropion and 
placebo groups were observed in the aforementioned studies at the 12 week point (Hurt et al., 
1997; Jorenby et al., 1999; Hays et al., 2001), it is also possible is that the relatively short-term 
duration of the present study was insufficient to detect medication effects with this particular 
sample of weight-concerned women. That is, it may be that bupropion’s effects are delayed until 
weight gain secondary to prolonged abstinence is perceived as problematic enough to justify re-
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initiating smoking as a weight control aid. Thus, it is possible that greater weight gains 
associated with longer periods of prolonged abstinence (i.e., in excess of 11 weeks) are necessary 
for bupropion to decrease the probability of relapsing among women who report being worried 
about post-cessation weight gain prior to treatment (e.g., either by reducing weight gain itself or 
by decreasing concerns about weight gain). These explanations are admittedly speculative, and 
answering this question will ultimately require a larger sample size, a longer-term follow-up 
assessment, and a careful examination of changes in concerns about post-cessation weight gain 
and actual changes in body weight. 
Although the percentage of racial/ethnic minorities was relatively small in this study 
(11%), initial results indicated that non-Caucasian participants tended to withdraw from the 
study within the first two weeks, and therefore were presumed to be nonadherent and relapsed. 
Of the six participants who failed to complete a minimum threshold of the medication regimen, 
two were African-American and one was Native Hawaiian/Pacific Islander. This finding is 
consistent with a body of research showing that racial and ethnic minorities commonly manifest 
poorer adherence rates in comparison to the majority of the population. These racial/ethnic 
disparities in adherence may be attributable to several impediments, including financial 
constraints, logistical barriers, cultural barriers, and environmental stressors (National Institutes 
of Health, 1/25/01). Although this study was not designed to assess factors influencing 
racial/ethnic differences in adherence, it is plausible that any of these factors were related with 
medication non-completion among these three individuals. For example, the counseling groups 
were composed primarily of Caucasian participants and the research staff was composed entirely 
of Caucasian individuals, and this may have inadvertently created cultural barriers for 
engagement and retention in the trial. However, it is important to note that the number of 
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minority non-completers was quite small, so this statistically significant effect may have been 
due to chance, as well.  
The present findings suggest that personality constructs may improve the prediction of 
adherence. As expected, results demonstrated that individuals with lower levels of 
conscientiousness were less likely to complete the minimum duration of the medication regimen, 
and among medication completers, lower conscientious levels predicted poorer adherence 
throughout the 90-day period. The notion that conscientiousness is associated with adherence is 
intrinsically appealing in that this trait is defined largely by self-control, which involves active 
planning, organizing, and executing tasks, as well as a lack of impulsiveness (Costa and McCrae, 
1992). The conscientiousness factor of the full-scale NEO-PI-R (Costa and McCrae, 1992) 
includes six facets: competence, order, dutifulness, achievement striving, self-discipline, and 
deliberation. These facets are negatively related to characteristics typical of individuals who are 
impulsive, unsocialized, and sensation seeking (Gilbert, 1995). Thus, it may be that individuals 
with low levels of conscientiousness tend to choose behaviors that promise immediate rewards 
rather than behaviors that may have potential long-term benefits (e.g., adhering to a 
pharmacotherapy regimen). Unfortunately, the short-form NEO-FFI does not include personality 
facets and therefore does not allow for the examination of specific aspects of conscientiousness 
that may be responsible the factor’s association with mediation adherence. 
Secondary analyses revealed that openness to experience was positively associated with 
medication adherence. This effect was not hypothesized a priori since the other Big Five 
dimensions of have received the majority of attention in health behavior research, and in fact, no 
published findings exist on openness to experience and treatment adherence. Still, there are a few 
published studies on the association between openness to experience and various health-related 
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phenomena. Booth-Kewly and Vickers (1994) reported that openness to experience was 
positively associated with substance use and associated high-risk behaviors (e.g., driving while 
intoxicated). Shadel et al. (2000) found in a sample of 37 smokers that openness to experience 
was positively associated with nicotine dependence, but was unrelated to duration of recent 
cessation attempt and recent exposure to cigarette smoke. In another recent study, Duberstein et 
al. (2003) reported that older primary care patients scoring higher on openness to experience 
tended to report better perceived physical functioning.  
Closer examination of the openness to experience dimension provides some insight into 
possible processes underlying the openness to experience/medication adherence relationship 
found in the present study. The openness to experience dimension is characterized by curiosity 
and receptiveness to new ideas and experiences, in addition to diverse interests, mindfulness, and 
resourcefulness (Costa & McCrae, 1992). Individuals scoring high on this factor also tend to be 
cognitively flexible and intelligent (McCrae & John, 1992). Thus, it is possible that individuals 
who are open to experience are more willing to try out new behaviors, such as experimenting 
with nicotine in the first place and then taking a psychotropic medication to facilitate smoking 
cessation. It is also conceivable that, given the positive association between the openness to 
experience and intelligence quotient (e.g., Holland, Dollinger, Holland, & MacDonald, 1995), 
individuals scoring high on this personality dimension may be better able to problem-solve when 
obstacles to adherence arise and may be more apt to remember to take their medication as 
prescribed. Indeed, medication adherence has been characterized as a memory task that may 
require substantial cognitive demands (Gould, McDonald-Miszczak, & King, 1997) and 
adherence rates decrease as the complexity of a medication regimen increases (e.g., Trotta et al., 
2002).  
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Secondary analyses also showed that perceived social support and medication outcome 
expectancies measured at Week 6 were positively associated with 90-day medication adherence. 
However, the same psychosocial constructs measured at baseline were not significantly 
associated with medication adherence. The discrepant effects of social support on adherence are 
somewhat difficult to explain given the evidence that perceived social support functions 
somewhat like a trait. For instance, the six-week test-retest reliability of ISEL scores was .76 in 
the present study, and other researchers have reported an equally high test-retest reliability of 
ISEL scores over six months (e.g., r = .74, Cohen et al., 1985). Moreover, a recent quantitative 
genetic study demonstrated that genetic factors account for a significant proportion of the 
variance in ISEL scores (Raynor et al., 2002). One possible explanation for the discrepant social 
support findings is that the salutary effects of perceived support may occur while engaging in the 
stressful quit process and during the early maintenance phase rather than the relatively quiescent 
time prior to quitting. This conceptualization of social support is commonly referred to as the 
buffering hypothesis (Cohen & Wills, 1985) and previous smoking cessation (Cohen et al., 1988) 
and chronic disease adherence-related research (e.g., Christensen, Turner, Slaughter, & Holman, 
1989; Littlefield, Rodin, Murray, & Craven, 1990) is consistent with this explanation. Thus, it is 
possible that the generally mixed findings in the social support/adherence literature may be due 
to the failure to examine the predictive utility of repeated measures of social support, particularly 
during times of high stress. Another possibility is that favorable adherence during the first six 
weeks of treatment was positively reinforced by social support from participants’ family, friends, 
and others support network members, which in turn contributed to more favorable adherence 
(Czajkowski et al., 1998). Finally, the inconsistency of the present social support findings also 
 94
raises the possibility that various aspects of social support (e.g., information, tangible, etc.) may 
affect adherence differentially.  
The discrepant associations between baseline and Week 6 medication outcome 
expectancies12 and medication adherence may be attributable to the influence of adhering to 
several weeks of the medication regimen and group smoking cessation therapy (Czajkowski et 
al., 1998). Participants taking the medication as prescribed during the early phases of changing 
their smoking behavior may have developed the expectation that the medication would facilitate 
prolonged smoking abstinence. These positive beliefs may have subsequently contributed to the 
maintenance of favorable adherence. Those who manifested less favorable regimen adherence, 
on the other hand, may not have developed the expectation that the medication would be of much 
assistance in quitting smoking and therefore did not adhere as well.  
Some discussion of unsupported links between the other psychosocial variables and 
medication adherence is warranted. The influence of agreeableness on medication adherence was 
suggested by the broader health-behavior change literature but was not observed in the present 
study. It is possible that only certain aspects of the agreeableness versus antagonism dimension 
are deleterious to medication adherence. According to the five-factor model, two forms of 
hostility exist: (1) neurotic hostility, exemplified by frequent and intense experience of anger, 
frustration, and rage, and (2) antagonistic hostility, exemplified by cynicism, rudeness, and 
condescension (Costa & McCrae, 1992). As previously discussed, in one of the only studies 
examining the effect of hostility on medication adherence, Christensen et al. (1997) found that an 
                                                 
12 It is interesting to note that there was no difference (p = .27) in medication outcome expectancies between 
individuals taking bupropion (M = 48.06) and placebo (M = 45.04) at the 6-week assessment, indicating that double-
blinding procedure was successful and medication expectancies were a nonspecific aspect of the medication 
regimen. 
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index of antagonistic hostility, the Cook-Medley Hostility scale (Cook & Medley, 1954), was 
linked to less favorable medication and dietary adherence among hemodialysis patients. Thus, it 
is conceivable that differentiating agreeableness into its two forms would have shown that 
antagonistic hostility is predictive of medication adherence in the present study. Although the 
full-scale NEO-PI-R indexes antagonistic hostility via the trust and compliance facets of 
agreeableness factor, its short-form NEO-FFI does not permit an examination of these facets. 
The medication self-efficacy expectancies subscale measured at baseline was unrelated to 
adherence. Although this experimenter-developed measure demonstrated adequate internal 
consistency, it is possible that the restricted variability reduced its predictive utility. Specifically, 
the possible range of the medication self-efficacy subscale was from 11 to 77, the sample mean 
was quite high, M = 66.8 (SD = 7.8), and the distribution was highly negatively skewed, 
skewness = -.92 (SE = .23). By comparison, although the possible range of the medication 
outcome expectancies subscale was similar (13 to 91), the sample mean was lower (M = 58.5), 
the standard deviation was larger (SD = 11.5), and the distribution approximated normality, 
skewness = .22 (SE = .23). Moreover, this null finding is consistent with the previously 
mentioned postulation that the relative ease of the present study’s two pills per day regimen 
would reduce the predictive power of self-efficacy expectancies, particularly in comparison to 
medication outcome expectancies. 
The hypothesized influence of side effects (alone or in combination with depressive 
symptoms) on medication adherence was not confirmed, as well. Since the levels of pretreatment 
physical symptoms and Week 5 side effects were not unusual per se, it is unlikely that ceiling or 
floor effects were problematic. One possibility is that specific side effects have a deleterious 
effect on medication adherence, whereas others have either no effect or even a positive effect on 
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adherence. For instance, it is conceivable that newly developed insomnia would have a greater 
prognostic significance than other side effects, such as decreased appetite. Since a composite 
index of 38 side effects was computed without respect to particular symptoms in the present 
study, this possibility is speculative.  
4.3 Prediction of Smoking Cessation 
The hypothesized association between medication adherence and prolonged smoking abstinence 
was supported. Importantly, this association was statistically significant despite a lack of 
evidence that level of medication (bupropion versus placebo) influenced smoking cessation. 
Since regression analysis does not provide information regarding direction of causality, a cross-
lagged panel design was used to test hypotheses regarding the temporal nature of the medication 
adherence/smoking abstinence relationship. Cross-lagged panel correlations showed that both 
adherence and point-prevalence smoking abstinence were significant antecedents of one another. 
That is, medication adherence during the second 30-day period significantly predicted 
subsequent point-prevalence abstinence at Day 84 of the study period, and point-prevalence 
abstinence at Day 56 significantly predicted medication adherence during the third 30-day 
period. The former effect may be interpreted as support for the main effect of adherence 
hypothesis; the latter effect may be interpreted as failure to quit smoking or maintain early 
abstinence resulted in women considering the medication to be inefficacious and therefore 
deciding to discontinue adhering to the prescribed regimen. Although results showed that 
adherence was the stronger antecedent of the two behaviors, it is important to note that these two 
directional effects are not mutually exclusive. In other words, both of these processes may have 
been functioning within the same time frame.  
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The effect of smoking relapse on subsequent regimen adherence has clinically relevance 
in that continued use of pharmacotherapies after initially failing to quit smoking may contribute 
to successful long-term cessation. Specifically, in a post-hoc examination of a large-scale 
smoking cessation RCT (viz., Jorenby et al., 1999), Jamerson and her colleagues (2001) found 
that, among patients who failed to quit smoking within the first three weeks of treatment, those 
taking SR bupropion alone or in combination with nicotine patch were more successful in long-
term smoking cessation (through 52 weeks) than those taking placebo. Thus, the positive 
correlation between point-prevalence abstinence at Day 56 and subsequent medication adherence 
during the third 30-day period observed in the present study, together with findings reported by 
Jamerson et al. (2001), suggests that individuals failing to quit smoking early in treatment should 
be urged to continue adhering to their pharmacotherapy regimen because this may lead to 
successful behavior change in the long run. 
The positive correlation between medication adherence during the second 30-day period 
and subsequent smoking status at Day 84 is consistent with a similar effect found by Killen et al. 
(1997) in a nicotine patch intervention study as well as a growing body of research involving a 
variety of health-related behaviors and outcomes. In designing this study, it was believed 
advantageous to include several psychosocial variables that, heretofore, had not been used to 
examine pathways underlying the main effect of adherence. However, adjustment for these 
psychosocial variables did not attenuate the main effect of adherence on smoking abstinence. 
Notwithstanding these null findings, it remains possible that favorable medication adherence was 
representative behavior of a subset of “good patients” who also were making a thoroughly 
determined effort to quit smoking (Hitsman et al., 2001). Although differing aspects of 
multicomponent treatment regimens are typically thought to be unrelated (e.g., Orme & Binik, 
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1989), a moderately strong correlation (r = .46, p = .000) between participants’ medication 
adherence and attendance with behavioral treatment sessions in the present study is consistent 
with this explanation.  
The search for psychosocial processes underlying the main effect of adherence was 
disappointing, but the exploration of mediational effects between psychosocial variables and 
smoking abstinence was more fruitful. Post-hoc analyses demonstrated that two mediators—
medication adherence and Week 6 medication outcome expectancies—together accounted for 
72.5% of the variance shared between openness to experience and prolonged smoking 
abstinence. Stated differently, individuals scoring high on openness to experience tended to 
maintain smoking abstinence more readily than individuals scoring low on this factor in part 
because they adhered to the medication regimen more closely and also because they believed the 
medication was helping to ameliorate factors associated with maintaining smoking abstinence. 
That medication outcome expectancies functioned as a mediator may be interpreted as high-
openness to experience individuals may be more amenable to believing in the efficacy of the 
study medication in a double-blind medication trial. Post-hoc analyses also revealed that 
medication adherence accounted for 37.2% of the variance shared between Week 6 social 
support and prolonged smoking abstinence. Although research has shown that social support is 
one of the most reliable predictors of successful smoking cessation (Mermelstein, Cohen, 
Lichtenstein, Baer, & Kamarck, 1986), this is the first study to demonstrate that 
pharmacotherapy adherence is a behavioral pathway for this association. Interestingly, post-hoc 
analyses also revealed that, if Week 6 social support had not been examined concurrently, 
medication adherence would have mediated the association between Week 6 depressive 
symptoms and prolonged smoking abstinence. Thus, previous research on depressive symptoms 
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and treatment adherence in the absence of relevant correlates, such as social support, should be 
interpreted with caution. Finally, although agreeableness was associated with increased 
likelihood of maintaining smoking abstinence, the mechanisms underlying this association 
remain unclear given that this personality factor was uncorrelated with medication adherence. 
Since it is common practice to operationalize medication adherence with one index, the 
examination of the relative prognostic significance of the six summary measures of adherence 
yielded unique information. It was particularly interesting to find that the index of drug holidays 
was the strongest predictor of smoking abstinence. It suggests that failing to take a medication 
for one or more days may increase the likelihood of experiencing a smoking relapse to a greater 
extent than other forms of nonadherence, such as regularly underdosing (e.g., taking one instead 
of two pills per day). Indeed, there is a growing appreciation for the effects of drug holidays on 
health outcomes (c.f., Heynen, 1999). For instance, a study on HIV medication adherence 
showed that drug holidays from protease inhibitors were significantly associated with the onset 
of drug-resistant HIV mutations (Vanhove, Schapiro, Winters, Merigan, & Blaschke, 1996). 
However, this research has focused singularly on the effects of non-adherence to active 
medication regimens, and as such, it provides minimal insight into pathways underlying the 
consequences of holidays from both bupropion and placebo regimens that were observed in the 
present study. 
4.4 Limitations 
The interpretations of this study’s results should be qualified for several reasons. Foremost, in 
comparison to the broader population of smokers, the present sample was relatively homogenous 
and restricted in composition. In addition to being concerned about post-cessation weight-gain, 
participants were exclusively women, primarily Caucasian, and well educated. These volunteers 
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were highly motivated to quit smoking and were willing to travel to an urban medical center for 
extensive screening and attend 18 counseling sessions over a year. They were also willing to take 
a study medication for six months, even though the possibility of being randomized to bupropion 
or placebo was entirely dependent on chance. The limited generalizability of the present findings 
is underscored by meta-analytic findings showing that nicotine replacement therapy interventions 
are more effective when participants are self-referred rather than invited (Tang, Law, & Wald, 
1994). Alternatively, one could consider that these highly-selected participants might represent a 
group of refractory smokers, given the well-replicated finding that treatment seekers in a variety 
of clinical and research settings have more severe and complicated behavioral and psychological 
problems (e.g., Wilfley, Pike, Dohm, Striegel-Moore, & Fairburn, 2001; Kessler et al., 1999;  
Strohmetz, Alterman, & Walter, 1990).  
Like most prospective intervention trials, a potential limitation of this study was the 
existence of missing data. Roughly 21% of participants (who were not withdrawn from the 
medication regimen due to adverse effects) were missing one or more psychosocial variables at 
baseline or measures of side effects at Weeks 2, 3, or 5. Although careful exploratory analyses 
did not reveal any patterns to the missingness, it is possible that the use of non-missing data only 
in primary analyses biased the findings in some unidentified manner. Also, secondary analyses 
included psychosocial indices measured at Week 6 that involved additional missing data. In 
order to maintain a sample size comparable to the one used in primary analyses, missing data for 
these indices were imputed from their respective non-missing means. Although results involving 
these measures were comparable with and without imputation, caution should be used when 
interpreting these findings due to the possibility that results were biased toward significance 
(Harrell, 2001). 
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Although the use of electronic monitors to measure medication adherence has several 
benefits, this methodology incurred some problems in the present study. One of the primary 
benefits of the EEM methodology is to capture continuous medication-taking behavior in real-
time for subsequent computer upload, but small minority of participants encountered events of 
daily living13 that resulted in loss of varying degrees of data. Also, a minority of participants in 
the present study anecdotally reported that the pill container was bulky and inconvenient and 
therefore transferred the medication to another pill container. Some of these women reported that 
they continued to open their MEMS cap routinely to portray proper adherence, whereas others 
indicated that they were perfectly adherent but did not bother to feign adherent behavior. 
Another weakness of using of MEMS as the sole measure of adherence in this study is that it did 
not provide any information regarding purpose of nonadherence. Two different types of 
nonadherence are thought to exist: intentional and inadvertent (Bauman, 2000). Intentional 
nonadherence is characterized by deliberately deciding not to adhere, whereas inadvertent 
nonadherence is characterized by forgetting about the regimen or experiencing barriers to 
adherence. As psychosocial predictors may vary across purpose of nonadherence, it is 
unfortunate that this type of information was not measured in this study.  
The research design of this study was non-experimental, so any causal inferences about 
relationships among the psychosocial variables, medication adherence, and smoking abstinence 
would be unsubstantiated. The limited causal information derived from the mediational analyses 
exemplifies this interpretive limitation. If an association between two variables attenuates or 
                                                 
13 For example, one participant’s MEMS cap was confiscated at an airport-screening checkpoint due to its perceived 
security risk. Another instance of lost data occurred when a participant fell into a lake and lost her purse, which was 
carrying the MEMS cap. 
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disappears when the variability of a third variable is removed, it is tempting to conclude that the 
third variable caused the relationship between the other two. However, this reasoning is flawed 
in that it is not known whether the particular third variable examined is responsible for the 
relationship between the two variables or whether the relationship is due to yet another variable 
correlated with the third variable. Similarly, caution should be exercised when interpreting 
results from the cross-lagged panel design analyses, which were based on correlational analyses. 
Path analyses would have strengthened inferences from this passive-observational study (Kazdin, 
1992), but statistical power considerations would have necessitated a much larger sample size 
(Bentler & Chou, 1987). Another design limitation of this study was the limited duration of 
smoking cessation follow-up. That is, given that life-long abstinence is the ultimate goal of 
smoking cessation interventions, the SRNT subcommittee on abstinence measures recently 
recommended that follow-up assessments be at least 6 or 12 months post-cessation (Hughes et 
al., 2003).   
Finally, this research was exploratory in nature and therefore results should be considered 
tentative. The preliminary state of knowledge on adherence to smoking cessation 
pharmacotherapies dictated that the primary goal of this study was to identify plausible 
predictors and consequences of adherence, rather than to test an existing theory. One 
consequence of not using an overarching theoretical model to guide selection and integration of 
psychosocial parameters is that conclusions are restricted to only those variables deemed worthy 
of inclusion. Although the putative predictors of medication adherence were carefully chosen, 
potentially important variables were not examined, and as a result, the processes underlying the 
main effect of adherence on smoking cessation were not elucidated. In particular, a potentially 
important omission was the failure to measure motivation to adhere to the treatment regimen. 
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Given the growing body of research supporting the application of the stages of change model to 
smoking behavior (Prochaska, 1996), as well as the time-varying effects of psychosocial 
characteristics observed in the present study, it may have been fruitful to repeatedly measure 
fluctuations in readiness to adhere to the medication regimen and to maintain smoking behavior 
changes throughout this study. 
4.5 Future Research 
Notwithstanding the aforementioned limitations, the findings from the present study point to 
several directions for future research. The most conspicuous need is to replicate these results 
with samples more representative of the broader population of smokers. This would involve 
studying adherence to smoking cessation pharmacotherapy, for instance, among men, 
racial/ethnic minorities, and individuals in community settings. Importantly, many of the present 
study’s inferential limitations could be addressed with methodological adjustments. To begin 
with, a longer-term follow-up assessment of smoking status at 6 or 12 months would provide 
more convincing information about the long-term consequences of adhering to the medication 
regimen. Secondly, recently developed multilevel modeling techniques (c.f., Bock, 1989; 
Longford, 1993) could be used to incorporate all participants’ data, thereby maximizing 
statistical power and minimizing potential bias associated with casewise deletion or imputation 
characteristic of traditional regression analysis. Thirdly, a substantially larger sample size would 
allow for the utilization of other advanced statistical techniques, such as structural equation 
modeling, which add flexibility for testing a wider array of hypotheses as well as increasing 
confidence in causal inferences. In particular, path analysis is the preferred choice to conduct a 
cross-lagged panel design because it allows for multiple, simultaneous statistical tests of partial 
correlations among measured variables (Finkel, 1995). Another advantage of testing a cross-
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lagged panel design with path analysis is that several nested models could be compared with 
inferential statistics (i.e., χ2 tests; see Nauta, Kahn, Angell, & Cantarelli, 2002). For example, 
several of the following hypothesizes could have been tested via path analysis: (1) no relation 
between medication adherence and smoking abstinence (baseline model), (2) adherence is an 
antecedent in the adherence/smoking abstinence relationship, (3) smoking abstinence is an 
antecedent, (4) both adherence and smoking abstinence are antecedents (i.e., a reciprocal 
relationship), and (5) adherence and smoking abstinence as equally strong antecedents of one 
another (i.e., comparing the model fit of hypotheses 4 and 5 would inform on whether one 
direction is more robust than the other). Moreover, a larger sample size would allow for the 
examination of the main effect of adherence in the placebo condition alone. This would provide a 
relatively pure test of this non-specific effect given that individuals taking sugar pills would not 
be affected pharmacologically. Fourthly, the facets of the higher order domains comprising the 
Five-Factor Model of Personality should be measured with the full-scale NEO-PI-R (Costa & 
McCrae, 1992) in order to characterize potentially specific pathways among personality, 
medication adherence, and smoking cessation. Finally, future research should also include 
multiple measures of medication adherence in order to triangulate on “true” medication 
adherence and minimize error variance. For example, blood assays would provide important 
biological verification of EEM-measured medication adherence, and if unannounced, would 
minimize “white coat adherence” characteristic of scheduled tests.  
Another direction for future research would be to utilize an assessment methodology that 
could potentially enhance the predictive power of psychosocial variables on medication 
adherence. As evidenced by the discrepant results from Baseline versus Week 6 measures of 
social support and medication outcome expectancies in the present study, repeatedly measuring 
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putative psychosocial predictors of medication adherence may be particularly advantageous. 
Since standard paper-and-pencil measures are notoriously unreliable (e.g., Stone, Shiffman, 
Schwartz, Broderick, & Hufford, 2002), a recently developed approach for assessing 
psychosocial and behavioral processes in natural settings, called Ecological Momentary 
Assessment (EMA; Stone & Shiffman, 1994), could be utilized to measure psychosocial 
characteristics and smoking behavior in near real-time. EMA approaches utilize repeated self-
report diary assessments, often via hand-held computers, to examine phenomena as they occur in 
real life, therapy minimizing cognitive recall biasing and maximizing ecological validity (Stone 
& Shiffman, 1994). The EMA-based self-report diary would yield information on within-subject 
fluctuations of psychosocial states that could be linked with adjacent within-subject changes in 
EEM-measured medication adherence by means of within-subjects repeated measures analyses. 
Also, individual differences in psychosocial characteristics, such as personality factors, could be 
used to predict within-subject changes in medication adherence on a daily basis rather than with 
global summary measures. In a similar vein, a time-varying covariate survival analysis with 
EEM-measured medication adherence and EMA-measured smoking behavior would also yield 
fine-tuned information on the temporal precedence of these two behaviors. For example, this 
approach would provide a careful test of whether drug holidays pose an acute risk for subsequent 
smoking relapses or vice versa.  
Like the present study, every previous attempt to ascertain processes underlying the main 
effect of adherence on health outcomes has yielded null findings. These attempts have consisted 
of statistically controlling for a variety of psychosocial and biomedical variables only to have the 
main effect of adherence remain significant. In future studies of this phenomenon, a different 
approach would be to explore whether latent factors explain phenotypic covariation among 
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relevant parameters. Specifically, confirmatory factor analysis could be used to examine whether 
one or more latent variables would satisfactorily explain covariation among various indices of 
treatment adherence. Although the significant correlation between medication adherence and 
group therapy attendance was the only adherence-related covariation reported in the present 
study, it is plausible that adherence to other treatment recommendations overlapped, as well. For 
instance, participants who manifested favorable medication adherence and group therapy 
attendance may also have followed recommendations from the behavior therapist to reduce 
exposure to caffeine and alcohol (i.e., due to their conditioned associations with smoking 
behavior, as well as the latter substance’s deleterious influence on cognitive processes associated 
with problem-solving and overcoming high-risk situations). It is also possible that this 
hypothetical subset of adherent participants made other self-initiated health-related lifestyle 
changes, such as increasing physical activity or improving dietary intake behaviors. Likewise, in 
addition to examining latent factors underlying potential covariation among adherence-related 
behaviors, it is possible that phenotypic covariation among parameters involved in the 
mediational effects observed in the present study (e.g., openness to experience/medication 
adherence/smoking abstinence) could be accounted for by one or more common factors. Indeed, 
a common latent factor underlying medication adherence and smoking cessation would shed 
light on why adjusting for psychosocial variables has had no impact on this correlation. 
If phenotypic structural equation modeling supported the existence of one or more 
common latent factors, the exploration of the relative contributions of genetic and environmental 
influences on variation and covariation of medication adherence, its psychosocial correlates, and 
smoking cessation may also be a fruitful area for future research. Since almost all behavioral 
phenotypes are determined in part by genetic factors (Plomin, DeFries, McClearn, & Rutter, 
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1997), it is surprising that the enormous literature on medication adherence does not include any 
quantitative genetic studies of this behavior. In the present study, test-retest reliabilities of 
medication adherence over the three 30-day periods of this study ranged from very strong (r = 
.76) to moderately strong (r = .42), suggesting that this behavior may be a relatively stable 
individual difference. Also, previous research has shown that other health-related behaviors, such 
as physical activity (Maia, Thomis, & Beunen, 2002) and food intake (Heitmann, Harris, Lissner, 
& Pedersen, 1999), are genetically influenced. Thus, it is plausible to hypothesize the genetic 
factors may significantly influence adherence to smoking cessation pharmacotherapy. Moreover, 
behavior genetic studies have shown that several of the psychosocial correlates of medication 
adherence in the present study are affected by genetic factors. Loehlin (1992) analyzed 
personality data from family, twin, and adoption studies with structural equal modeling and 
reported heritability estimates of 38 percent for conscientiousness and 45 percent for openness to 
experience. Bergeman et al. (1993) conducted a twin/adoption study with the Big Five factors 
and reported heritability estimates of 29 percent for conscientiousness and 40 percent for 
openness to experience. With a twin study design, Raynor et al. (2002) reported that genetic 
factors accounted for 59% of the variance of ISEL scores and other researchers have reported 
substantial genetic effects on other measures of social support (e.g., Kessler, Kendler, Heath, 
Neale, & Eaves, 1992; Bergeman, Plomin, Pedersen, & Nesselroade, 1990). Likewise, based on 
their review of behavior genetic studies, Heath and Madden (1995) concluded that genetic 
factors account for a significant amount of the variance in risk of initiation and persistence of 
long-term smoking behavior, and a recent twin study showed that genetic influences accounted 
for 54% of the variance in risk of smoking cessation failure (Xian et al., 2003). Given the 
observed phenotypic associations and previously reported genetic etiology, it is plausible to 
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hypothesize that the covariation between medication adherence and one or more of these 
psychosocial characteristics may be accounted for by common genetic influences. It is also 
conceivable that the main effect of adherence on smoking cessation may be explained in part by 
common etiological factors, possibly genetic in nature. The use of multivariate structural 
equation modeling within a genetically informative family study would permit testing of such 
hypotheses. 
Heretofore, all of the suggestions for future research have involved variations of passive-
observational, or correlational, designs. Given the inferential limitations of such designs, it 
would be imperative to conduct experimental research in order yield causal information related 
to pharmacotherapy adherence and smoking behavior. One such possibility is the utilization of a 
balanced placebo design (Marlatt & Rohsenow, 1980), which involves experimentally 
manipulating instructions (Told Active versus Told Placebo) and pharmacological content of a 
drug (Received Active versus Received Placebo) in a 2 x 2 factorial design. This approach would 
allow for the examination of main and interaction effects of the actual drug and participants’ 
expectations about its effects on medication adherence and smoking behavior.   
Future experimental research should also focus on developing effective interventions to 
enhance adherence and maximize health-related outcomes. Unfortunately, a recent literature 
review showed that the relatively few interventions designed to help patients follow medication 
prescriptions were poorly designed and generally ineffective (Haynes et al., 2000). Based on the 
present study’s findings, two general approaches for developing more effective interventions are 
indicated. One approach would be to develop interventions that would modify factors associated 
with medication adherence. For instance, the positive associations between Week 6 social 
support, medication adherence, and smoking cessation suggest that interventions designed to 
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enhance social support may be efficacious, particularly in the first few weeks following 
medication initiation and smoking cessation. Although none of the treatment studies reviewed by 
Haynes et al. (2000) demonstrated the effectiveness of social support interventions per se, 
previous research has shown that such treatments are effective in enhancing adherence to other 
preventive health regimens, such as weight control (e.g., Brownell, Heckerman, Westlake, 
Hayes, & Monti, 1979; Wing & Jeffery, 1999), diabetes management (e.g., Shenkel et al., 1985-
1986), hypertension control (e.g., Morisky et al., 1985), and smoking cessation (e.g., West, 
Edwards, & Hajek, 1998).  
Another approach to developing effective interventions would be to match treatments to 
individual differences in psychosocial characteristics associated with medication adherence 
and/or smoking cessation. Based on the present study, low-conscientious individuals would 
comprise one subset of female smokers at high-risk for medication nonadherence. A variety of 
empirically-supported techniques exist that may be particularly beneficial to such individuals, 
including directly observed medication consumption (Chaisson et al., 2001), tailoring the 
regimen to daily habits (Haynes et al., 1976), and appointment and prescription refill reminders 
(Peterson et al., 1984). Importantly, the usage of such techniques among high-conscientiousness 
individuals may be superfluous and cost-ineffective. By the same token, high-openness to 
experience smokers may be more receptive to alternative forms of therapy (e.g., meditation, 
imagery), whereas low-openness to experience smokers may favor more straightforward 
approaches (e.g., informational support, practical advice; Miller, 1991). Indeed, the provision of 
treatments based on individualized reasons for nonadherence and smoking relapse may be 
particularly efficacious in utilizing limited resources on a public health scale.   
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5 SUMMARY AND CONCLUSIONS 
 
The present study assessed rates, predictors, and sequelae of adherence to a medication regimen 
among women participating in a smoking cessation program. Results supported several 
hypotheses: (1) overall medication adherence was less than optimal throughout the 90-day study 
period and adherence rates decreased during each successive 30-day period; (2) 
conscientiousness predicted medication completion and 90-day medication adherence, and (3) 
90-day medication adherence predicted prolonged smoking abstinence. Follow-up analyses 
indicated that: (1) conscientiousness did not predict prolonged smoking cessation, (2) medication 
adherence predicted subsequent point-prevalence smoking abstinence, point-prevalence smoking 
abstinence predicted subsequent medication adherence, and medication adherence was the 
stronger antecedent of the two behaviors; and (3) among six summary indices of medication 
adherence, the measure of drug holidays was the strongest predictor of prolonged smoking 
abstinence. Contrary to expectations, agreeableness, depressive symptoms, medication self-
efficacy expectancies, (baseline) medication outcome expectancies, (baseline) social support, and 
medication side effects did not aid in predicting medication adherence. Secondary analyses 
indicated that: (1) openness to experience, Week 6 medication outcome expectancies, and Week 
6 social support predicted 90-day medication adherence, (2) openness to experience and Week 6 
social support predicted prolonged smoking abstinence, and (3) 90-day medication adherence 
mediated the association between openness to experience and smoking abstinence, and between 
Week 6 social support and smoking abstinence. 
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In conclusion, given that medication adherence was less than optimal and was positively 
associated with smoking cessation outcome in the present study, further research on predictors of 
pharmacotherapy adherence is warranted. Moreover, the present findings indicate that efforts to 
enhance adherence by either modifying psychosocial variables that are somewhat amenable to 
change (e.g., social support or medication outcome expectancies), or by matching treatments to 
levels of characteristics that are comparatively stable (e.g., conscientiousness and openness to 
experience) may be particularly efficacious in improving medication adherence rates, and 
possibly enhancing smoking cessation outcomes. 
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APPENDIX A 
 
Study Medication Expectancies Questionnaire  
 
Instructions:  Individuals in the process of quitting smoking may experience uncomfortable 
symptoms. Use the scale below to rate your beliefs about how the Study Medication will affect 
YOUR symptoms and how it will affect YOUR quit attempt. For questions 1-13, please circle 
the number that best describes how much you agree with each question using the following 
scale:  
 
1 = Not at all agree, 4= Somewhat agree, 7 = Completely agree. 
 
How much do you believe that the Study Medication will… 
                                           
                             Not at all       Somewhat        Completely 
                                        agree                     agree                 agree 
                 
1.  reduce irritable feelings associated               1     2     3     4     5     6     7      
with quitting smoking? 
 
2.  reduce feelings of hunger?                            1     2     3     4     5     6     7      
         
3.  decrease worries about gaining weight?               1     2     3     4     5     6     7      
      
4.  reduce cravings to smoke?                 1     2     3     4     5     6     7      
                 
5.  help you to quit smoking permanently?    1     2     3     4     5     6     7      
 
6.  lead you to experience uncomfortable               1     2     3     4     5     6     7      
     physical side effects? 
 
7.  reduce negative mood associated with     1     2     3     4     5     6     7      
quitting smoking? 
 
8.  minimize weight gain after quitting smoking?    1     2     3     4     5     6     7       
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How much do you believe that the Study Medication will… 
 
                Not at all       Somewhat            Completely 
                                        agree                     agree                 agree 
 
 
9.  reduce sleep problems associated with     1     2     3     4     5     6     7      
quitting smoking? 
 
10.  reduce anxious feelings associated with     1     2     3     4     5     6     7      
  quitting smoking? 
 
11.  reduce restlessness associated with     1     2     3     4     5     6     7      
  quitting smoking? 
 
12.  reduce concentration difficulties associated     1     2     3     4     5     6     7  
       with quitting smoking?      
 
13.  be helpful to you overall?      1     2     3     4     5     6     7 
 
 
 
Instructions:  The Study requires you to take the Study Medication twice every day, once in the 
morning and once in the evening, for 6 months. Some situations may make it difficult to stick 
with the schedule for taking the Study Medication. Use the scale below to rate your confidence 
in sticking with the Study Medication schedule under a variety of conditions. For questions 14-
24, please circle the number to the right of each item that best describes your confidence level 
using the following scale: 
 
1 = Not at all confident, 4 = Somewhat confident, 7 = Extremely confident. 
 
How confident are you that you will take the Study Medication … 
 
          Not at all   Somewhat      Extremely  
              confident   confident      confident 
 
14.  for the first 3 months?    1     2     3     4     5     6     7      
 
15.  if your daily routine changes?   1     2     3     4     5     6     7      
 
16.  if you are traveling?    1     2     3     4     5     6     7      
 
17.  if you aren’t feeling well?   1     2     3     4     5     6     7      
  
18.  if it’s the weekend?    1     2     3     4     5     6     7      
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How confident are you that you will take the Study Medication … 
 
          Not at all   Somewhat      Extremely  
              confident   confident      confident 
 
 
19.  if you are not at home?    1     2     3     4     5     6     7      
  
20.  if you are feeling discouraged about your  1     2     3     4     5     6     7      
attempt to quit smoking?  
 
21.  if you think the study medication  1     2     3     4     5     6     7      
is not helping you? 
 
22.  if people close to you tell you they   1     2     3     4     5     6     7      
think the study medication is not   
helping you? 
 
23.  if you experience minor physical side  1     2     3     4     5     6     7      
effects? 
 
24.  if you gain a significant amount of  1     2     3     4     5     6     7      
weight? 
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Appendix B 
 
Diagnostic Analyses 
 
 Before formal multiple linear regreession modeling began, data were edited for 
diagnostic and, if necessary, remedial action. Variables were initially converted to standardized 
z-scores and examined for outliers (⎟ z⎟ > 3.29). Data points over three standard deviations from 
the mean were excluded from data analysis. Next, scatter plots with fitted Lowess regression 
lines of the predictor variables against medication adherence were used to examine the linearity 
of bivariate relationships among predictor variables and medication adherence. These plots did 
not reveal any non-linear (e.g., quadratic, cubic) relationships. A preliminary regression model 
with all predictor variables force entered was fitted to examine the multivariate normality 
assumption. Since residual plots of predictors versus fitted data were uniformly scattered, the 
multivariate normality assumption was supported and the assessment of univariate normality for 
the predictors was not necessary (Tabachnick & Fidell, 1996).  
 Consistent with suggestions of Neter, Kutner, Nachtsheim, and Wasserman (1996), final 
diagnostics were performed once a model was fitted. A plot of the residuals against the fitted 
values was obtained in order to assess the appropriateness of the multiple regression function and 
the constancy of the error variances. Residuals were plotted against each of the predictor 
variables to check for normality and predicted values were plotted against absolute residuals to 
check for homoscedasticity. A normal probability plot of the residuals was also assessed for 
departures from linearity. The variance inflation factor was examined for values greater than 10, 
which is the typical cutoff for multicollinearity violations. Studentized deleted residuals were 
examined with the Bonferroni simultaneous procedure to diagnose outlying or extreme criterion 
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observations, whereas centered leverage values were used to identify outlying predictor 
observations. Finally, DFITS AND DFBETAS measures were used to determine whether or not 
the outliers were influential (i.e., a case is influential if its exclusion causes major changes in the 
fitted regression function).  
 For multiple logistic regression models, problems with linearity were assessed with the 
Box-Tidwell transformation test and outlying or overly influential cases were analyzed via 
studentized residual and DFBETA analysis (Menard, 2002). 
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